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1. Summary 
The success of checkpoint inhibition has changed treatment algorithms in several 
tumor entities within the past years. Treatment success has mainly been observed 
in cancers with an inflamed microenvironment and an immune infiltrate leading to 
upregulation of checkpoint molecules on tumor cells as a means of immune 
escape. Hence, in tumor entities with a low endogenous anti-tumor response, such 
as acute myeloid leukemia (AML), checkpoint inhibition as monotherapy has so far 
shown no clinical benefit. Therapeutic vaccination based on autologous dendritic 
cells (DCs) pulsed with leukemia-associated antigens (LAA) is able to elicit anti-
leukemic immunity. The combination with checkpoint inhibitors might enable to 
enhanced anti-leukemic immune responses in two ways: First, by blocking the 
interaction between checkpoint molecules on anti-leukemic T cells and upregulated 
checkpoint molecules on the leukemic target cells; and second, by enhancing the 
initial interaction between T cells and DCs which constitutively express inhibitory 
checkpoint molecules on their surface. Thus, a combinatorial therapy of DC 
vaccination and checkpoint blockade, in particular for cancers with a low 
endogenous anti-tumor response is a promising treatment strategy. 
We have implemented a phase I/II first-in-human clinical study using monocyte-
derived toll-like receptor (TLR) 7/8-matured next-generation DCs loaded with wilms 
tumor 1 (WT1), preferentially expressed antigen in melanoma (PRAME) and 
cytomegalovirus (CMV)pp65 RNA as post-remission therapy of AML patients with 
a non-favorable risk profile. 
DC vaccination was feasible and safe and induced antigen-specific immune 
responses. AML-specific T cell responses correlated with improved relapse-free 
survival (RFS), especially in younger patients (≤ 65 years). 
Despite a strong co-stimulatory profile, DCs also expressed co-inhibitory 
checkpoint ligands. We examined those inhibitory interactions using an in vitro T 
cell-DC coculture. DC-activated T cells upregulated programmed cell death protein 
1 (PD-1) and lymphocyte activation gene 3 (LAG-3), while DCs expressed the 
respective ligands programmed cell death protein ligand 1 (PD-L1) and major 
histocompatibility complex (MHC) class-II. As hypothesized, we demonstrated that 
blockade of PD-1 and particularly of LAG-3 by suitable blocking antibodies 
enhanced DC-induced T cell activation. 
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We conclude that TLR7/8-matured next-generation DC vaccination induces 
vaccine antigen-specific immune responses which may lead to delay or prevention 
of relapse. Our in vitro data supports the rationale of combining DC vaccination with 
PD-1 and/or LAG-3 blockade to further augment anti-leukemic immune responses 
and improve clinical outcome. 
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2. Introduction 
 
2.1 Acute Myeloid Leukemia  
Acute myeloid leukemia (AML) is a hematological malignancy, which is defined by 
disrupted differentiation and uncontrolled proliferation of myeloid progenitor cells in 
bone marrow and blood (Dohner, Weisdorf et al. 2015).This results in proneness 
to infections and anemia and ultimately in multiple organ failure and death. AML is 
the most frequent leukemia among adults with a median age of 68 years and an 
incidence rate of 19,520 new cases and 10,670 deaths in the US in 2018 
(Lichtenegger, Krupka et al. 2017, Siegel, Miller et al. 2018).  
AML is a genetically and clinically heterogeneous disease with a very poor 
prognosis. Despite the strong need for improvement, the treatment has barely 
changed over the past decades: The standard treatment after diagnosis is a high 
dose induction chemotherapy comprising three days of anthracycline and seven 
days of cytarabine. This so called “3+7” regimen induces complete remission (CR) 
in about 80% of the patients (Dohner, Estey et al. 2010, Burnett, Wetzler et al. 2011, 
Ferrara and Schiffer 2013, Lichtenegger, Krupka et al. 2017). However, the risk of 
relapse is high due to chemorefractory leukemic cells. A post-remission therapy to 
eliminate residual leukemic cells is therefore mandatory (Reinisch, Chan et al. 
2015). 
Usually, patients with a favorable genetic risk profile get additional cycles of 
chemotherapy as consolidation, whereas the method of choice for AML patients 
with high relapse risk is allogeneic hematopoietic stem cell transfer (HSCT). HSCT 
was the first curative immunotherapy for patients with hematological malignancies 
(cure rate over 50%). Its clinical benefit relies in particular on the so-called graft-
versus-leukemia effect: allogeneic T and natural killer (NK) cells of the donor 
recognize and target malignant cells of the recipient. However, the beneficial 
potential of anti-leukemic responses is opposed by the individual risk of graft-
versus-host disease. In addition, the donor availability is challenging (Stelljes, Krug 
et al. 2014, Kassim and Savani 2017). Especially elderly patients (< 60 years) are 
often not medically fit for intensive therapies including HSCT (Klepin, Rao et al. 
2014).  Thus, there is a high medical need for the development and improvement 
of novel therapies.  
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2.2 Cancer Immunotherapy in AML 
Cancer immunotherapy aims to direct the body´s own immune system against 
malignant tumor cells. It represents one of the most promising novel strategies to 
cure cancer and to decrease relapse rates (Rusch, Bayry et al. 2018). Various T 
cell based immunotherapeutic strategies to eliminate chemorefractory leukemic 
cells are currently under preclinical- and clinical investigation (Lichtenegger, 
Krupka et al. 2015, Lichtenegger, Krupka et al. 2017). The most prominent are:  
• T cell engaging antibody based approaches to recruit T cells to target antigen 
expressing tumor cells (Jin, Lee et al. 2009, Laszlo, Gudgeon et al. 2014). 
• Adoptive T cell transfer (TCR-, or CAR T cell therapy) to augment autologous 
T cells in number and tumor antigen specificity (Xue, Gao et al. 2005, 
Spranger, Jeremias et al. 2012, Brenner 2013, Pizzitola, Anjos-Afonso et al. 
2014, Prommersberger, Jetani et al. 2018, Gomes-Silva, Atilla et al. 2019)  
• Dendritic cell vaccination to induce strong and durable tumor antigen-specific 
T cell responses (Van Tendeloo, Van de Velde et al. 2010, Anguille, Willemen 
et al. 2012, Khoury, Collins et al. 2017, Weinstock, Rosenblatt et al. 2017).	 
• Immune checkpoint blockade to enhance or reactivate preexisting anti-tumor 
T cell responses (Alatrash, Daver et al. 2016).  
The future will show the advantages and disadvantages of each anti-leukemic 
treatment strategy in AML. 
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2.3 Dendritic Cell Vaccination in AML 
2.3.1 Vaccination Strategies 
The induction of tumor antigen-specific immune responses is the primary goal in 
cancers with a low mutational burden and no (or only low) preexisting endogenous 
anti-tumor immune responses, such as AML (Yarchoan, Hopkins et al. 2017). 
Consequently, leukemia-specific neoantigens arised by mutations and restricted to 
the tumor are very rare in AML. 
Leukemia-associated antigens (LAAs) are endogenous antigens which are 
overexpressed by leukemic cells compared to healthy tissues. Thus, LAAs can be 
presented via peptide MHC-complexes (pMHC) to T cells. Despite immunological 
tolerance towards self-antigens, these pMHC-T cell interactions were shown to 
induce detectable anti-LAA-specific immune responses (Rosenberg 1999, Anguille, 
Van Tendeloo et al. 2012). In the last decades, numerous LAAs were identified 
(Greiner, Li et al. 2005). Nevertheless, the clinical outcome of LAA peptide 
vaccination in AML still remains unsatisfying. A major difficulty of peptide 
vaccination is to overcome T cell tolerance against self-restricted LAAs and 
transformation into efficient specific T cell responses eradicating the tumor 
(Schmitt, Casalegno-Garduno et al. 2009, Subklewe, Geiger et al. 2014).  
As the most potent professional antigen-presenting cells (APCs) DCs are capable 
to initiate both, tolerance as well as strong long-lasting (innate and adaptive) 
immune responses (Banchereau and Steinman 1998, Steinman 2001). In the 
context of an inflammatory response, DCs undergo a maturation process that 
includes upregulation of cell surface MHC and co-stimulatory molecules and 
secretion of numerous cytokines including IL-12p70 which are crucial for the 
induction of primary T cell responses (Sallusto and Lanzavecchia 2002). Thus, 
mature tumor-associated antigen (TAA)-presenting DCs are highly eligible as 
cellular adjuvant for targeted therapeutic vaccination (Timmerman and Levy 1999).  
Numerous in vivo experiments have already demonstrated the capacity of injected 
TAA-loaded DCs to induce TAA-specific T cell responses and tumor regression.  
The therapy relies on patient-derived DCs that are ex vivo manipulated- and TAA -
loaded. Crucial parameters for DC vaccination are inter alia the source of DC 
precursors (PBMCs, primary DCs,..), DC maturation protocol (TLR agonist based 
etc), target antigen (TAA/LAA), way of antigen loading, route of application (peptide 
pulsing, in vitro-transcribed RNA electroporation etc), and application interval 
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(Saxena and Bhardwaj 2018). Monocyte-derived DCs have been reported to induce 
the most potent immune responses. However, there are also alternative attempts 
using DC-like constructs (Rosenblatt, Stone et al. 2016, Lichtenegger, Krupka et 
al. 2017, Sprooten, Ceusters et al. 2019). 
 
2.3.2 Ongoing Phase II Clinical Trials on DC-Vaccination as Therapy in AML 
Different treatment strategies of high-risk AML patients are currently under 
investigation. Noteworthy is a personalized DC-AML hybridoma vaccination 
strategy, which relies on the fusion of autologous AML cells with autologous DCs. 
This hybridoma is thought to stimulate broad anti-tumor responses and was tested 
in 17 AML patients in CR. It was well tolerated and showed an augmentation of 
leukemia-specific T cell responses as well as durable remissions (Rosenblatt, 
Stone et al. 2016, Nahas, Stroopinsky et al. 2019). However, this study comes with 
a substantial bias regarding the selection of long-term survivors, which complicates 
further conclusions (Lichtenegger, Krupka et al. 2017). 
Most clinical trials are based on in vitro differentiated DCs from monocytes, but also 
some from CD34+ progenitors. Different ways of antigen loading are tested. A 
common approach is DC pulsing with a single tumor-associated protein or a peptide 
fragment. Specific immune responses were observed in vitro, whereas clinical 
benefit failed in vivo (Lesterhuis, Schreibelt et al. 2011). Major issues with peptide-
pulsing are the restriction of T cell responses to the selected epitope and 
unattended post-translational modifications of the tumor antigen. DC 
electroporation with mRNAs circumvents this problem (Lesterhuis, De Vries et al. 
2010). This approach has already been successfully tested in phase I/II studies for 
post-remission therapy of AML: A vaccination trial using hTERT mRNA 
electroporated DCs demonstrated vaccine antigen-specific T cell responses and 
RFS after a median observation time of 52 months in 58% of the vaccinated 
patients (n=19) (Khoury, Collins et al. 2017). In another trial, DCs loaded with WT1 
mRNA induced anti-leukemic responses in 43% and molecular remission in 30% 
of the patients (n=30). A correlation between overall survival (OS) and WT1-specific 
CD8+ T cell responses was thereby demonstrated (Van Tendeloo, Van de Velde et 
al. 2010, Anguille, Van de Velde et al. 2017).  
In those studies DC maturation was performed using the gold standard cocktail 
consisting of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and prostaglandins 
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(PGE2) (Jonuleit, Kuhn et al. 1997). While this protocol was developed to increase 
the expression of DC maturation markers as well as immunostimulatory and 
migratory capacities, the resulting cells lack secretion of IL-12p70, which is crucial 
to induce optimal anti-tumor immune responses. IL-12p70 leads to a Th1 
polarization of CD4+ cells, which, in turn, support the activation of both, TAA-
specific CD8+ T cells as well as of NK cells (Carreno, Becker-Hapak et al. 2013).  
Inflammatory cytokine secretion by DCs is typically triggered by activation of toll-
like receptors (TLR). Physiologically, TLRs signal upon recognition of pathogen 
patterns. Many of those receptors exist with different functions and pathways to be 
involved in (Schreibelt, Tel et al. 2010). In the case of IL-12p70, TLR7/8 and TLR3 
signaling pathways need to get activated (Napolitani, Rinaldi et al. 2005). 
Furthermore, the standard protocols for DC differentiation from monocytes were 
based on seven days (7d) of cell culture. An accelerated production of clinical-
grade mature DCs lowers the expenses of manufacture. In addition, the faster 
differentiation might reflect more appropriate the situation in vivo (Burdek, Spranger 
et al. 2010, Subklewe, Geiger et al. 2014). 
 
2.3.3 New Generation DC Vaccine for Immunotherapy of AML 
Our group developed a three-day (3d) GMP compliant protocol for the generation 
of DCs based on a TLR7/8 agonist (Subklewe, Geiger et al. 2014). Monocytes are 
isolated and subsequently stimulated by addition of GM-CSF and IL-4. The 
following day, DCs are matured by a 24h in vitro culture using a cocktail composed 
of the synthetical TLR7/8 agonist R848 together with PGE2 as well as the cytokines 
TNF-α, IL-1β and IFN-γ (Zobywalski, Javorovic et al. 2007, Beck, Dorfel et al. 2011, 
Subklewe, Geiger et al. 2014). We tested our new cocktail in comparison to the 
gold standard cocktail for the maturation of monocyte-derived 3d- and 7d-DCs, 
respectively. Similar to DCs generated based on a standard 7d-protocol, 3d-DCs 
displayed a mature surface phenotype and demonstrated their capacity to take up 
and present antigens and were able to stimulate antigen-specific T cells. However, 
they had several superiorities: Increased yields of viable DCs were obtained. The 
relative surface-expression of the co-stimulatory molecules CD80 and CD86 was 
higher than the one of the co-inhibitory molecule PD-L1. Dramatically higher levels 
of IL-12p70 were secreted upon CD40-CD40-ligand interaction whereas IL-10 
secretion, which would support an undesired Th2 polarization of CD4+ T cells was 
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low. Moreover, 3d-DCs demonstrated an enhanced migratory ability in vitro 
compared to 7d-DCs. This observation was in line with a substantial expression of 
the chemokine receptor CCR7 (Burdek, Spranger et al. 2010, Lichtenegger, 
Mueller et al. 2012). Thus, TLR7/8-matured 3d-DCs demonstrated a significantly 
improved ability for Th1 polarization and antigen-specific activation of autologous 
T cells compared to DCs generated with the standard cocktail. In addition, NK cells 
were highly increased. The protocol was also evaluated for the generation of 
mature 3d-DCs from monocytes of AML patients in remission. (Zobywalski, 
Javorovic et al. 2007, Spranger, Javorovic et al. 2010, Beck, Dorfel et al. 2011, 
Lichtenegger, Mueller et al. 2012, Subklewe, Geiger et al. 2014). 
Based on these DCs we conducted a phase I/II proof-of-concept clinical study, 
which has been recently completed (publication I). DCs were pulsed with mRNA 
encoding the LAAs WT1, PRAME, and CMVpp65 as adjuvant and control antigen 
for vaccination of AML patients in CR with a non-favourable risk profile and not 
eligible for allogeneic HSCT (NCT01734304). 
 
2.3.4 The Clinical Study Antigens WT1, PRAME, and CMVpp65  
A fundamental part of the DC vaccination study design is the selection of suitable 
TAAs to elicit beneficial anti-tumor immunity and to prevent adverse events. WT1 
and PRAME are both oncogenic LAAs with high expression on AML bulk cells 
(>85% and 65%) and on leukemic stem cells. Both were shown to be immunogenic 
and have already proven clinical efficacy and safety (Li, Giannopoulos et al. 2006, 
Keilholz, Letsch et al. 2009, Rezvani, Yong et al. 2009, Maslak, Dao et al. 2010, 
Quintarelli, Dotti et al. 2011). 
WT1 is a zinc finger transcription factor and overexpressed in a wide range of 
cancers (including ovarian cancer) while it is rarely found in normal adult tissue. 
WT1-specific T cells were detected in both, healthy individuals and in AML patients. 
AML patients treated with WT1 peptide-based vaccines demonstrated immune 
responses in clinical trials (Mailander, Scheibenbogen et al. 2004, Rezvani, Yong 
et al. 2008, Keilholz, Letsch et al. 2009, Subklewe, Geiger et al. 2014).  
PRAME is a cancer testis antigen. It contributes to oncogenesis by impeding cell 
differentiation, growth arrest, and programmed cell death/apoptosis. High mRNA 
amounts of PRAME were detected in AML patients and correlated to the disease 
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(Greiner, Ringhoffer et al. 2004, Wadelin, Fulton et al. 2010, Subklewe, Geiger et 
al. 2014).  
Human cytomegalovirus (CMV) is a member of the herpes virus family. Its 65-kDa 
phosphoprotein (pp65) has been verified as a main immunodominant and 
immunogenic target antigen for CMV-specific CD8+ T cells. Hence, it was selected 
as a control and helper antigen for the DC study (Grigoleit, Kapp et al. 2007, 
Subklewe, Geiger et al. 2014).  
 
2.3.5 Boosting DC-induced T Cell Responses 
Besides high surface expression of co-stimulatory molecules, co-inhibitory 
molecules, such as PD-L1, have also been described to be expressed on DCs 
(Lichtenegger, Mueller et al. 2012). In this regard, it is noteworthy that MHC class-
II, which is highly expressed on 3d-DCs can act as an inhibitory ligand of 
lymphocyte activation gene 3 (LAG-3), an immune checkpoint receptor particularly 
upregulated on activated T cells (more detailed in 2.4). Blockade of those 
interactions by monoclonal antibodies is a promising approach to reverse the 
inhibitory effects (Pardoll 2012). Therefore, combination of DC vaccination with 
checkpoint inhibition is a promising strategy to further enhance immune responses, 
particularly in cancer entities with a low endogenous anti-tumor response (Hobo, 
Maas et al. 2010). 
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2.4 Immune Checkpoint Blockade in Cancer Therapy 	
Immune checkpoint molecules are major targets in the field of cancer research. 
Inhibitory checkpoint receptors are mainly upregulated on activated T cells, while 
the interacting ligands were found to be constitutively expressed on the surface of 
APCs and/or upregulated on inflamed tissues usually triggered by inflammatory 
cytokines (such as IFN-γ). The physiological role of immune checkpoints is 
silencing of immune responses to protect from collateral tissue damage and 
autoimmunity. However, inhibitory immune checkpoint ligands can also be 
expressed or upregulated on cancer cells in the context of inflammation. This 
provides an escape mechanism for tumor cells from successful immune recognition 
and elimination (Pardoll 2012, Chen and Flies 2013).  
Numerous of those molecules have been discovered in the last decades. Cytotoxic 
T lymphocyte associated protein-4 (CTLA-4) and programmed cell death protein-1 
(PD-1) are the most prominent ones (Ishida, Agata et al. 1992, Krummel and Allison 
1995, Weber 2010). The Blockade of the inhibitory interactions with their ligands 
(CD80/86 and PD-L1/-L2, respectively) using monoclonal antibodies demonstrated 
successful enhancement of anti-tumor immune responses in preclinical and clinical 
studies (Hodi, Mihm et al. 2003, Iwai, Terawaki et al. 2005, Pardoll 2012, Kyi and 
Postow 2014). This resulted in the FDA approval of antibodies against CTLA-4, PD-
1 and PD-L1 for application in advanced solid tumors but also in classical Hodgkin 
lymphoma (Ansell, Lesokhin et al. 2015, Ottaviano, De Placido et al. 2019).	In 2018, 
James P. Allison and Tasuku Honjo won the Nobel Prize in medicine for the 
discovery of these checkpoint inhibition approaches (Bazhin, Amedei et al. 2018, 
Smyth and Teng 2018).	
Despite the clinical success of checkpoint inhibitors in terms of raised life 
expectancy, there still remains a large population of cancer patients who does not 
benefit from the treatment. Responses are limited to cancer entities with a high 
tumor mutational burden and side effects are still challenging (Topalian, Hodi et al. 
2012, Ansell, Lesokhin et al. 2015, Sharma, Hu-Lieskovan et al. 2017, Seidel, 
Otsuka et al. 2018, Ottaviano, De Placido et al. 2019). Novel targets and 
combinatorial strategies for a broader application are sought after. 
Studies with checkpoint inhibitors for the treatment of AML are still in early 
development and mainly restricted to PD-1 so far. 
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2.4.1 PD-1 
Programmed cell death protein 1 (PD-1; CD279) belongs to the B7/CD28 family. 
Besides activated CD4+ and CD8+ T cells, PD-1 expression has been shown by B 
cells, monocytes, DCs and NK cells (Liang, Latchman et al. 2003, Okazaki and 
Honjo 2006). PD-1 interacts with PD-L1 (CD274) as well as with PD-L2 (CD273). 
PD-L1 is basically little expressed on normal tissues. However, it was shown to be 
upregulated by various tumor entities in inflammatory conditions (Taube, Anders et 
al. 2012). High PD-L1 surface expression on tumor cells correlates with decreased 
immune responses. PD-L2 is expressed on APCs and was also detected on certain 
solid tumors (Hobo, Hutten et al. 2018).  
Some AML mouse models demonstrated the enhancement of anti-leukemic 
immune responses through blockade of the PD-1/PD-L1 pathway (Saudemont and 
Quesnel 2004, Zhang, Gajewski et al. 2009). The detection of PD-L1 and PD-L2 
expression on human AML cells is heterogeneously reported among different 
studies (Chen, Liu et al. 2008, Zhang, Zhang et al. 2015, Annibali, Crescenzi et al. 
2018). Nevertheless, PD-L1 was inducible upon stimulation with proinflammatory 
cytokines (Kronig, Kremmler et al. 2014). Similarly, PD-1 expression on T cells from 
AML patients was not always increased compared to healthy controls depending 
on the status of the disease, origin and T cell population (Schnorfeil, Lichtenegger 
et al. 2015, Tan, Chen et al. 2017, Jia, Wang et al. 2018). In a phase I clinical study 
of patients with advanced hematologic malignancies, the PD-1 modulating antibody 
Pidilizumab (CT-011) showed only one minimal response among the examined 
AML patients (Berger, Rotem-Yehudar et al. 2008). However, recent evidence 
suggests that Pidilizumab binds primary another target Delta-like 1 while the effects 
on PD-1 are only secondary and restricted to non-glycosylated and 
hypoglycosylated forms of this checkpoint molecule. Nevertheless, this underlines 
the acknowledged findings that response to checkpoint inhibition requires 
endogenous anti-tumor immune responses and correlates with the tumor 
mutational burden (Rizvi, Hellmann et al. 2015, Schumacher and Schreiber 2015, 
Yarchoan, Hopkins et al. 2017). As AML belongs to the cancer entities with low 
mutational rates, the clinical use of checkpoint inhibitors as a monotherapy is less 
encouraging in comparison to other hemato-oncological malignancies (Boddu, 
Kantarjian et al. 2018, Seidel, Otsuka et al. 2018, Curran and Glisson 2019) ASH 
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abstract/Blood (2016) 128(22):764). 
The combination of checkpoint inhibitors with T cell inducing strategies are 
therefore of high interest. DC vaccination is a promising approach to induce T cell 
responses. T cell responses can be enhanced through blockade of upregulated 
checkpoint molecules (Ribas, Comin-Anduix et al. 2009, Curran and Glisson 2019). 
We examined the expression of several inhibitory checkpoint molecules on TLR7/8-
matured next-generation DCs. PD-L1 and in particular MHC class-II which also acts 
as an inhibitory ligand of LAG-3, were highly expressed. DC-activated T cells 
upregulated corresponding receptors PD-1 and LAG-3. Therefore, we 
hypothesized that blockade of those interactions with suitable blocking antibodies 
further increase T cell activation by DCs (ASH abstract/Blood (2016) 128(22):764). 
 
2.4.2 LAG-3  
The inhibitory checkpoint molecule lymphocyte activation gene 3 (LAG-3; CD223) 
is a member of the immunoglobulin superfamily. LAG-3 is related to CD4 and also 
interacts with MHC class-II molecules on APCs, however with a higher affinity 
(Triebel, Jitsukawa et al. 1990, Demeure, Wolfers et al. 2001, Li, Wang et al. 2007). 
LAG-3 is expressed on activated CD4+ and CD8+ T cells and Tregs (Huang, 
Workman et al. 2004), as well as on certain NK cells (Huard, Tournier et al. 1998), 
B cells (Kisielow, Kisielow et al. 2005) and plasmacytoid DCs (Andreae, Buisson et 
al. 2003, Workman, Wang et al. 2009).  
LAG-3 is localized in endosomal compartments in resting T cells, but it gets quickly 
upregulated on the T cell surface upon activation (Bae, Lee et al. 2014). 
Metalloproteases control surface expression of LAG-3 via cleavage from the 
membrane (Li, Wang et al. 2007). The soluble LAG-3 isoform was shown to activate 
APCs but also the proliferation of tumor cells particularly with regard to chronic 
lymphocytic leukemia (Shapiro, Herishanu et al. 2017). LAG-3 signaling silences 
activation and expansion of CD4+ and CD8+ T cells (Workman and Vignali 2003). 
Therefore, LAG-3 receptors associate with the CD3-TCR complex during formation 
of the immunological synapse (Hannier and Triebel 1999). The interaction of LAG-
3 with MHC class-II molecules was shown to impede antigen-dependent activation 
of CD4+ T cells (Hannier, Tournier et al. 1998, Macon-Lemaitre and Triebel 2005, 
Hobo, Hutten et al. 2018) and a similar role of MHC class-II for CD8+ T cell 
activation is presumed (Matsuzaki, Gnjatic et al. 2010, Andrews, Marciscano et al. 
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2017). Nevertheless, the search for other binding partners is pursued. Galectin-3 
has been shown to mediate inhibition of CD8+ T cell responses via LAG-3 binding 
(Kouo, Huang et al. 2015). Furthermore, a role of LSECtin has been demonstrated 
in melanoma (Hemon, Jean-Louis et al. 2011) and Fibrinogen-like Protein 1 (FGL-
1) was recently discovered as a major inhibitory ligand of LAG-3 (Figure 1) (Wang, 
Sanmamed et al. 2019). LAG-3 were found to be co-expressed with PD-1 by T cells 
in numerous viral and tumor murine models and human ex vivo experiments 
(Wherry, Ha et al. 2007, Tian, Zhang et al. 2015, Zarour 2016). Consequently, 
double knockouts or double blockade showed synergy in anti-virus and anti-tumor 
immune responses (Woo, Turnis et al. 2012, Huang, Eppolito et al. 2015, Foy, 
Sennino et al. 2016).  
Monoclonal blocking antibodies targeting LAG-3 (relatlimab/BMS-986016, 
LAG525) alone or in combination with anti-PD-1 are currently assessed in clinical 
trials of patients with hematologic neoplasms/malignancies (NCT02061761, 
NCT03365791) (Long, Zhang et al. 2018, Andrews, Yano et al. 2019). Furthermore, 
dual-affinity re-targeting (DART) proteins targeting PD-1 and LAG-3 (MGD013 and 
FS118) are under current investigation. MGD013 is evaluated in phase I clinical 
studies for hematologic neoplasms (NCT03219268). 
Initial data from a clinical trial using relatlimab in combination with nivolumab 
demonstrated efficacy in melanoma patients refractory to immunotherapeutic 
pretreatments (NCT01968109). The combined therapy was safe, with a similar risk 
profile to nivolumab alone. In total, the treatment resulted in responses of 11.5% of 
the patients (n=68). In addition, a correlation between LAG-3 expression (≥1%) and 
therapeutic success has been observed (ESMO abstract/	 Ann Oncol (2017) 
28(Suppl_5):v605–49. doi:10.1093).  
A broad multiparameter flow cytometry analysis showed presence of LAG-3 
positive T cells in bone marrow samples from AML patients. Notably, it was shown 
that the frequency of PD-1/LAG-3 double-positive CD8+ and CD4+ effector T cells 
was increased in bone marrow of  AML patients compared to healthy donor controls 
(Williams, Basu et al. 2019). However, to this day, no clinical trials are testing the 
potential of LAG-3 blockade in AML. 
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Figure 1: Lymphocyte activation gene 3 (LAG-3) receptor and its ligands. Major 
histocompatibility complex class II (MHCII), Fibrinogen-like Protein 1 (FGL-1), Galectin-3 (GAL-3), 
Liver sinusoidal endothelial cell lectin (LSECtin) 
 
 
2.5 Aim of this Thesis 
In the first part of this doctoral thesis I conducted the analysis of patient data from 
our DC vaccination clinical trial with respect to vaccine antigen-specific immune 
responses, OS and RFS (publication I). In the second part of the thesis, my focus 
was on studying the enhancement of T cell responses through the addition of 
checkpoint inhibitors to T cell – DC interaction. In particular, I evaluated the 
augmentation of antigen-specific T cell responses through DCs with or without 
checkpoint inhibition, with focus on PD-1 and LAG-3 to assess weather blockade 
of inhibitory checkpoint interactions enhances DC-induced T cell activation 
(publication II).  
Results support the combination of therapeutic vaccines with checkpoint inhibition 
to augment antigen-specific T cell responses and reverse adaptive immune 
escape. The two publications are presented in the following chapter. 
  
Tumor cell CD4+ T cell
pMHCII
LAG-3
TCR
FGL-1GAL-3
LSECtin
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3. Publications 
 
3.1 Author Contributions Publication I 
 
„Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-
remission therapy in acute myeloid leukemia: results of a phase I trial.” 
 
Felix S. Lichtenegger, Frauke M. Schnorfeil, Maurine Rothe, Katrin Deiser, Torben 
Altmann, Veit L. Bücklein, Thomas Köhnke, Christian Augsberger, Nikola P. 
Konstandin, Karsten Spiekermann, Andreas Moosmann, Stephan Boehm, Melanie 
Boxberg, Mirjam H.M. Heemskerk, Dennis Goerlich, Georg Wittmann, Beate 
Wagner, Wolfgang Hiddemann, Dolores J. Schendel, Gunnar Kvalheim, Iris 
Bigalke, Marion Subklewe 
 
Journal of Clinical & Translational Immunology. 2020 Feb; doi: 10.1002/cti2.1117 	
The initial project idea of the clinical trial came from Felix Lichtenegger and Marion 
Subklewe. Together they planned the concept, all necessary requirements and 
designed the study protocol. Certain processes were supported by Wolfgang 
Hiddemann, Dolores Schendel, Gunnar Kvalheim and Iris Bigalke. 
The clinical trial was performed by medical doctors at the University Hospital 
Munich. Mainly by members of the Subklewe group: Felix Lichtenegger, Torben 
Altmann, Veit Bücklein, Thomas Köhnke, Georg Wittmann, Beate Wagner, and 
Marion Subklewe. Generation of the vaccine was performed at the Oslo University 
Hospital by Gunnar Kvalheim and Iris Bigalke.  
Immunomonitoring/Data acquisition was largely performed by Frauke Schnorfeil. 
The establishment and performance of the qPCR for the patients´ PRAME status 
on mRNA-levels, was done by me (Table 1). This included data analyses using the 
corresponding software.  
WT1-specific T cells (Figure 1f) were generated by Christian Augsberger and me.  
The data analysis/interpretation of all other experiments (Figure 1-5) was 
performed by Frauke Schnorfeil, Felix Lichtenegger, Marion Subklewe and me. 
Together, we evaluated and discussed the results. In particular, I created the 
swimmer plot (Figure 4) and the survival curves (Figure 5), and I analyzed and 
assigned the data of the matched AML-CG cohort (Figure 5 and Table S3) which 
was acquired by Felix Lichtenegger. Katrin Deiser, Chistian Augsberger, Nikola 
Konstandin, Karsten Spiekermann, Andreas Moosmann, Stephan Böhm, Melanie 
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Boxberg, and Mirjam Heemskerk were also involved in certain data acquisitions 
and/or interpretations.  
The final statistical analysis for the manuscript were performed by me. Former 
statistical analyses were performed by Felix Lichtenegger and Frauke Schnorfeil, 
Katrin Deiser, and Dennis Görlich.  
I designed all final figures and completely created the swimmer plot and the survival 
curves after consultation with Felix Lichtenegger and Marion Subklewe. Frauke 
Schnorfeil and Katrin Deiser performed the initial figure design. The manuscript 
was written by Felix Lichtenegger, Frauke Schnorfeil, Marion Subklewe, and me. 
 
3.2 Author Contributions Publication II 	
„Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-Presenting 
cells.” 
 
Maurine Rothe*, Felix S. Lichtenegger*, Frauke M. Schnorfeil, Katrin Deiser, 
Christina Krupka, Christian Augsberger, Miriam Schlüter, Julia Neitz and Marion 
Subklewe:  
 
Frontiers in Immunology. 2018 Feb; doi: 10.3389/ fimmu.2018.00385 	 *contributed equally 	
Based on the vaccination trial (publication I), my supervisors, Felix Lichtenegger 
Marion Subklewe, and I conceptualized this project. Together, we conceived and 
designed the experiments.  
All experiments (Figure 1-7) were performed either completely or mainly by me.  
Frauke Schnorfeil, Katrin Deiser and Christina Krupka constructively supported this 
project in terms of technical questions and data analyses. 
Christian Augsberger supported and guided me by the generation of WT1-specific 
T cells (Figure 7). 
Miriam Schlüter and Julia Neitz performed a few of the replicates (Figure 1-3).  
I performed data analysed in consultation with Felix Lichtenegger. 
Based on the data Felix Lichtenegger, Marion Subklewe, and I planned the figure 
design, which was independently executed by me.  
Felix Lichtenegger, Marion Subklewe, and I wrote the manuscript.  
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Abstract
Objectives. Innovative post-remission therapies are needed to
eliminate residual AML cells. DC vaccination is a promising
strategy to induce anti-leukaemic immune responses. Methods.
We conducted a first-in-human phase I study using TLR7/8-
matured DCs transfected with RNA encoding the two AML-
associated antigens WT1 and PRAME as well as CMVpp65. AML
patients in CR at high risk of relapse were vaccinated 109 over
26 weeks. Results. Despite heavy pretreatment, DCs of sufficient
number and quality were generated from a single leukapheresis in
11/12 cases, and 10 patients were vaccinated. Administration was
safe and resulted in local inflammatory responses with dense T-cell
infiltration. In peripheral blood, increased antigen-specific CD8+ T
cells were seen for WT1 (2/10), PRAME (4/10) and CMVpp65 (9/10).
For CMVpp65, increased CD4+ T cells were detected in 4/7 patients,
and an antibody response was induced in 3/7 initially seronegative
patients. Median OS was not reached after 1057 days; median RFS
was 1084 days. A positive correlation was observed between
clinical benefit and younger age as well as mounting of antigen-
specific immune responses. Conclusions. Administration of TLR7/8-
matured DCs to AML patients in CR at high risk of relapse was
feasible and safe and resulted in induction of antigen-specific
immune responses. Clinical benefit appeared to occur more likely
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
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in patients <65 and in patients mounting an immune response.
Our observations need to be validated in a larger patient cohort.
We hypothesise that TLR7/8 DC vaccination strategies should be
combined with hypomethylating agents or checkpoint inhibition
to augment immune responses. Trial registration. The study was
registered at https://clinicaltrials.gov on 17 October 2012
(NCT01734304) and at https://www.clinicaltrialsregister.eu
(EudraCT-Number 2010-022446-24) on 10 October 2013.
Keywords: acute myeloid leukaemia, cancer vaccines, clinical trials,
dendritic cell vaccination, immunotherapy
INTRODUCTION
Despite improvements in outcome over the past
decades, with 5-year survival rates climbing from
6.2% in 1975–1977 to 28.1% in 2008–20141 acute
myeloid leukaemia (AML) still has a dismal
prognosis.2 The major reason for the poor survival
rate is the high risk of relapse after intensive
induction therapy. The most successful strategy to
reduce the relapse rate is allogeneic
haematopoietic stem cell transplantation (allo-
HSCT).3 This potentially curative cellular
immunotherapy is based on the graft-versus-
leukaemia effect of allogeneic T cells. However,
because of high morbidity and mortality of this
therapy, there is a large group of AML patients
without this therapeutic option. Alternative
strategies for the activation of the immune system
aiming at eradication of chemorefractory residual
disease are therefore urgently sought after.
Vaccines induce and enhance autologous T cells
targeting intracellular leukaemia-associated
antigens (LAAs) and represent a promising
strategy. Immunisation with LAA peptides has
been studied in several clinical trials with
moderate clinical success so far.4,5 Optimisation of
vaccination might be achieved by the use of DCs.
As professional antigen-presenting cells, they
represent physiological candidates to induce
strong and durable immune responses.6,7 Several
strategies have been applied including
hybridomas of autologous DCs fused with
leukaemic blasts from primary diagnosis as a
vaccine in 17 AML patients in CR. Immunological
responses were observed, and 71% of the patients
were still in CR at a median follow-up of almost
5 years.8 Results of two major studies using
monocyte-derived DCs loaded with LAAs for post-
remission treatment of AML patients have been
reported: vaccination with DCs electroporated
with mRNA encoding hTERT resulted in antigen-
specific T-cell responses in 11/19 patients; RFS
after a median observation time of 52 months
was 58%.9 Within a phase II trial, an anti-
leukaemic response was detected in 13/30 patients
vaccinated with DCs loaded with wilms tumor 1
(WT1) mRNA. A molecular remission defined by
WT1 qPCR in the peripheral blood was achieved
in 9/30 patients, and RFS and OS at 5 years were
30.8% and 50.0%, respectively.10 In both
publications, DC maturation was achieved by a
combination of pro-inflammatory cytokines and
prostaglandins.11 While this protocol was
designed to promote migratory and
immunostimulatory properties of DCs, no IL-12p70
production was induced. However, IL-12 is a
crucial cytokine for both Th1 polarisation and NK
cell activation. In preclinical work comparing DCs
generated from peripheral blood mononuclear
cells (PBMCs) of healthy controls using different
maturation cocktails, we could show that the
addition of a toll-like receptor (TLR) 7/8 ligand to
the DC maturation cocktail results in enhanced T-
cell stimulation. In direct comparison to DCs
matured without a TLR agonist, the resulting DCs
are characterised by a higher expression of the
costimulatory molecules CD80 and CD86 and very
high production of bioactive IL-12p70. Both
in vitro and in vivo, we could show that these DCs
stimulate strong immune responses including
polarisation of CD4+ T cells to Th1, induction of
antigen-specific CD8+ T cells and activation of NK
cells.12,13 This approach can be translated to
monocytes derived from AML patients in CR, also
resulting in IL12p70-producing DCs with very
similar functional characteristics.14
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Hence, we have developed a good
manufacturing practice (GMP)-compliant protocol
for the generation of next-generation DCs,
combining a short, only 3-day differentiation
period with a novel maturation cocktail that
includes the TLR 7/8 agonist R848.15 As accounted
for in detail previously16 mRNAs encoding the
LAAs WT1 and preferentially expressed antigen in
melanoma (PRAME) as well as the viral control
antigen cytomegalovirus (CMV)pp65 were chosen
for antigen loading of three separate batches of
DCs by electroporation. Here, we describe the
results of a phase I first-in-human proof-of-
concept trial using next-generation DCs for post-
remission therapy of 10 AML patients in first CR
with a high risk of relapse (non-favorable risk
group or MRD positivity).
RESULTS
Patient characteristics
The characteristics of the 13 patients who were
enrolled into the study are shown in Table 1.
Twelve patients were positive for WT1 by qPCR at
primary diagnosis, four were positive for PRAME
by qPCR, and CMV serostatus was positive in four
patients before vaccination. Eastern Cooperative
Oncology Group (ECOG) performance status was 0
in two patients, 1 in 10 patients and 2 in one
patient.
Feasibility of vaccine generation and
administration
Twelve patients underwent leukapheresis for
production of the DC vaccine; patient #5
developed a leukaemia relapse in the short time
span between screening and planned
leukapheresis and was excluded from the study
before leukapheresis. Key figures of the
leukapheresis product are presented in
Supplementary table 1. A median of 1.25 9 1010
(range 0.6–2.8 9 1010) viable white blood cells
was collected per patient. Median monocyte yield
was 3.6 9 109 (range 1.0–7.5 9 109). Median DC
yield after electroporation was 3.65 9 108 (range
1.27–5.68 9 108). After quality control and
removal of retain samples, sufficient DCs for the
full schedule of 10 vaccinations (1.5 9 108 DCs)
were produced for 11 of 12 patients. For patient
#2, only six vaccinations were available as the
monocyte yield was low because of an
unexpected decrease in leucocyte count between
screening and leukapheresis (from 5.9 to
3.0 G L!1), and as DC recovery after
electroporation was suboptimal. Two patients
completed leukapheresis but were not vaccinated
because of early relapse during vaccine
production (#3) and because of characteristics of
the vaccine (#8, see below). Of the 10 patients
who actually initiated vaccination, seven
underwent the complete regular schedule of 10
vaccinations. Patient #2 received all six
vaccinations that were available, which was the
minimum required by the study protocol; patient
#4 developed a relapse after seven vaccinations
and received two further vaccinations in
combination with one cycle of 5-azacytidine; and
patient #7 also developed a relapse after seven
vaccinations and received three further
vaccinations in combination with two cycles of 5-
azacytidine. Two patients received further DC
vaccinations after the end of the study in
combination with 5-azacytidine in view of an
impending or established relapse: eight
vaccinations with five cycles of 5-azacytidine in
patient #1 and two vaccinations with one cycle of
5-azacytidine in patient #11. Median time from
CR/CRi to first vaccination was 110 days (range 34–
205 days), mainly because of further cycles of
consolidation therapy; median time from
leukapheresis to first vaccination was 25 days
(range 18–38 days).
Vaccine characterisation
All 12 generated DC preparations were tested for
their phenotype, migration capacity, cytokine
secretion, and processing and presentation of the
three selected antigens after RNA electroporation
(Figure 1 and Supplementary figure 1). For all
patients, the cells showed a typical DC phenotype
(CD14low and CD83+; Figure 1a). Expression of
various costimulatory or chemokine receptor
molecules was measured, and the specific
fluorescence intensity (SFI) was calculated
(Figure 1b). Median SFI was 124.6 for HLA-DR, 4.1
for CCR7, 35.6 for CD40, 31.6 for CD80, 35.4 for
CD86, and 21.5 for PD-L1. The ratio of CD86 to
PD-L1 expression as a potential measure of
positive costimulation was 1.25 in median. A
median of 74.5% (range 38.3–98.4%) of DCs
showed migration towards a CCL19 gradient
(Figure 1c). Ten of 12 DC preparations secreted
relatively high amounts of IL-12p70 (median of
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
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1845 pg/5 9 106 DC/24 h; range 470–4525 pg/
5 9 106 DC/24 h) and low amounts of IL-10
(median of 17.3 pg/5 9 106 DC/24 h; range 0–
241 pg/5 9 106 DC/24 h), as expected from our
previous experiments.12 DCs of patient #7 showed
very low IL-12p70 production (81.5 pg/5 9 106
DC/24 h) and no IL-10 production. DCs of patient
#8 showed high IL-12p70 production (1969 pg/
5 9 106 DC/24 h), but even higher IL-10
production (3031 pg/5 9 106 DC/24 h; Figure 1d).
Because of the unknown effects of vaccinations
with IL-10-producing DCs in the AML setting, this
patient was excluded from the study and not
vaccinated, although all release criteria for the
vaccine were fulfilled. Successful translation of
the electroporated RNA was proven by
intracellular staining of the DCs for the resulting
proteins (median SFI 2.36 for WT1, 1.44 for
PRAME, 1.53 for CMVpp65); DCs electroporated
with one of the other two RNA molecules served
as control (Figure 1e and Supplementary figure
2). Presentation of the antigens in the context of
HLA molecules was functionally proven by IFN-c
secretion of specific T-cell clones after coculture
with the different DC batches. Each T-cell clone
was preferentially stimulated by the respective
DC batch (Figure 1f).
Vaccine-induced immune responses
For all 10 vaccinated patients, local immune
response was measured 48 h after the fifth
vaccination by size of local erythema and
induration (Figure 2a). Vaccine site reaction was
detectable for all patients and all antigens.
Variability between patients was high, but no
significant differences were found between the
three antigens (WT1: median of 1.43 cm2, range
0.38–4.15 cm2; PRAME: median of 1.04 cm2,
range 0.28–3.46 cm2; CMV: median of 1.24 cm2,
range 0.38–3.14 cm2; Figure 2b). Skin biopsies
were taken from nine patients. Dense CD4+ and
CD8+ T-cell infiltration was seen by
immunohistochemistry (Figure 2c).
Immunomonitoring was performed on PBMCs
and plasma samples obtained before vaccination,
after five vaccinations and at the end of the
study. We found no major changes in the course
of the therapy with respect to absolute and
relative numbers of leucocytes, granulocytes,
monocytes, lymphocytes, CD3+ T cells, CD4+ T
cells, CD8+ T cells, CD19+ B cells or CD3-/CD16_56+
NK cells (data not shown). Antigen-specific T-cellTa
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Figure 1. Characterisation of DC phenotype, migration capacity, cytokine secretion and antigen processing and presentation. For all 12
generated DC preparations, surface expression of (a) the DC markers CD14 and CD83 and (b) various costimulatory or chemokine receptor
molecules was determined by flow cytometry. (c) Migration towards a CCL19 gradient was measured in a trans-well assay (2 technical replicates
per sample). (d) Secretion of IL-10 and IL-12p70 after CD40 ligation was analysed. To prove successful antigen translation and presentation after
RNA electroporation, DCs were (e) intracellularly stained for the resulting proteins and (f) used for stimulation of specific T-cell clones as
measured by IFN-c secretion (n = 3–7). For a, b and e, results are presented in box-and-whisker plots, with boxes representing the lower quartile,
the median and the upper quartile, while the whiskers show the minimal and the maximal values. For all other graphs, data shown reflect mean
and standard deviation.
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responses were measured by ELISpot and by
multimer staining, as shown for representative
patients in Figure 3 (complete immunomonitoring
data of these patients is presented in
Supplementary figure 3). An increased ELISpot
response after vaccination as defined by a ≥ 1.5-
fold increase of antigen-specific spot count was
detected in 2/10 patients for WT1 (Figure 3a), in 4/
10 patients for PRAME (Figure 3b), and in 9/10
patients for CMV (Figure 3c and d; Table 2). These
results were largely reflected by multimer staining:
an increased response as defined by a ≥ 2-fold
increase of multimer-positive CD8+ T cells was
detected in 1/6 patients for WT1, in 0/3 patients
for PRAME, and in 6/8 patients for CMV, with
limitations because of the availability of multimers
for the various HLA types (Table 2 and
Supplementary figure 4). CMV responses were
generally very high, with up to 15.9% of all CD8+
T cells stained with a single CMV multimer after
vaccination in a primarily seropositive patient (#6;
Figure 3g), and up to 9.6% of all CD8+ T cells
stained with a single CMV multimer after
vaccination in a primarily seronegative patient
(#10). Of note, also decreased frequencies after
vaccination were observed (Supplementary figure
3). Post-vaccination LAA-specific T-cell responses
were significantly lower, but still clearly detectable
in some patients (Figure 3e and f). In 4/7 patients
where a CMV-specific multimer for HLA type II was
available, an increase in antigen-specific CD4+ T
cells could be detected as well (Figure 3i; Table 2).
Vaccine-induced B-cell responses were measured
by detection of CMV antibodies. Of seven patients
who were CMV seronegative before vaccination,
antibodies against CMV were detected in three
patients after vaccination (#7, #10, #13), and one
patient had a borderline reaction after
vaccination (#2), while no antibodies against CMV
were detectable in three patients (#4, #9, #11).
Seroconversion as a result of primary CMV
infection was excluded by the methodology.
Clinical responses to vaccination
The vaccination protocol was generally very well
tolerated. All patients observed transient vaccine
site reactions (erythema, induration, pruritus) of
grade 1 intensity. Other frequent adverse events
were musculoskeletal pain (6/10), skin reactions
outside of vaccine sites (5/10), diarrhoea (4/10)
and fatigue (4/10). All potentially treatment-
Figure 2. Vaccine site reaction. (a) For all 10 vaccinated patients and all antigens, erythema and induration of the vaccine sites were observed.
(b) There was high variability between patients, but no significant difference between the three antigens in size of local reaction. (c)
Immunohistochemical analysis of skin biopsies at the vaccine sites revealed dense CD4+ and CD8+ T-cell infiltration (one representative example
shown).
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related adverse events reported by ≥ 2/10 patients
are listed in Supplementary table 2. All adverse
events were transient, and except for one grade 3
pyrexia, all adverse events were graded 1–2.
Because of limited patient numbers in the
phase I setting, clinical efficacy analysis was
purely exploratory. Vaccinated patients have
been observed for a median of 1057 (range
424–1449) days since primary diagnosis and a
median of 811.5 (range 293–1267) days since
first vaccination, with the cut-off on 31 March
2018. A swimmer plot of all 10 vaccinated
patients is depicted in Figure 4. Three patients
(#4, #7 and #11) relapsed already in the course
of the scheduled vaccinations, and two patients
(#1 and #2) relapsed after the end of the trial.
Of these five patients, only one (#4) is still alive
after several salvage therapies. The other five
vaccinated patients are still alive and in ongoing
CR. Aggregated survival data are shown in
Figure 5. Median OS has not yet been reached
(Figure 5a), and median RFS was 1084 days
(Figure 5b), with 50% of patients still relapse-
free at the end of observation. In a hypothesis-
generating analysis, these survival data compare
favorably to a closely matched patient cohort
from the AML-Cooperative Group (AML-CG)
registry (see Supplementary table 3 for patient
characteristics), where median OS was also not
yet reached at the end of observation (P-
value = 0.53; Figure 5a) and median RFS was
only 396 days, closely missing out on statistical
significance in spite of the small trial group (P-
value = 0.09; Figure 5b). Exploratory subgroup
analysis within the study cohort showed that
patients ≤ 65 years had significantly better OS
Figure 3. Representative examples of vaccine-induced immune responses. (a–d) PBMCs isolated before and after vaccination were tested for
antigen-specific T cells by ELISpot. Increased immune responses were detected for the LAAs WT1 (a) and PRAME (b) as well as for CMVpp65
(c, d). Both expansion of pre-existing immune responses (c) and induction of novel immune responses (d) were observed. (e–h) PBMCs isolated
before and after vaccination were tested for antigen-specific CD8+ T cells by multimer staining. Increased immune responses were detected for
the LAAs WT1 (e) and PRAME (f) as well as for CMVpp65 (g, h). Both expansion of pre-existing immune responses (g) and induction of novel
immune responses (h) were observed. (i) For CMVpp65, induction of antigen-specific CD4+ cells was also detected.
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(median not yet reached vs. 628 days; P-value =
0.0008; Figure 5c) and RFS (median not yet
reached vs. 294 days; P-value = 0.0122; Figure
5d) than patients > 65 years. Immune responders
as defined by expansion of antigen-specific T
cells against WT1 or PRAME showed a trend
towards better OS (median not yet reached vs.
976 days; Figure 5e) and RFS (median not yet
reached vs. 509 days; Figure 5f) than immune
non-responders, but statistical significance was
not reached because of the low patient number.
Specifically, the three patients ≤ 65 years who
showed an LAA-specific immune response (#6, #9
and #10) are all in ongoing CR.
Combination of 5-azacytidine with DC
vaccination as individual treatment attempt
Towards the end of the study treatment, patient
#1 developed an increase in MRD load, for both
WT1 copy number and frequency of leukaemia-
associated immunophenotype (LAIP), predicting
an impending relapse (Supplementary figure 4a).
After positive discussion with the ethics
committee of the LMU Munich and written
informed consent by the patient, we started an
individual treatment attempt combining 5-
azacytidine in the approved dose and schedule
(75 mg m!2 s.c. on days 1–7 of a 28-day cycle)
with next-generation DC vaccination on day 8 and
day 15 (Supplementary figure 4a). Vaccine site
reactions were found to be considerably
enhanced (Supplementary figure 4b), and the
frequency of LAA-specific T cells was increased
(Supplementary figure 4c). Two cycles of this
combination therapy lead to MRD conversion
(Supplementary figure 4a), which lasted for some
time before the patient relapsed almost a year
later. Similar treatment attempts were later
repeated for patients #4, #7 and #11, however not
in MRD situation, but in overt relapse. Similar
results in terms of local reaction and reduction of
disease burden were not observed in these cases.
DISCUSSION
As detailed above, two clinical trials using
monocyte-derived DCs loaded with LAA-specific
mRNA have already been published.9,10 In both
studies, DCs were activated by the classical
combination of pro-inflammatory cytokines and
prostaglandins,11 and mRNA encoding a single LAA
(hTERT and WT1, respectively) was used for
electroporation. Our trial decisively differed in two
important respects. First, the TLR7/8 ligand R848
was included into the maturation protocol,
resulting in DCs with improved immunostimulatory
properties including secretion of IL-12p70, as
demonstrated in detail previously.12 This study
represents the first-in-human trial applying these
Figure 4. Swimmer plot. Time point of first CR, vaccinations, potential other treatment modalities, and relapses, death or ongoing remission are
depicted for all patients treated within the trial.
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next-generation DCs to patients. Second, three
antigens were chosen for loading of separate DC
batches.16 Next to WT1, which is very frequently
overexpressed in AML and the most prominent
antigen in vaccination trials for AML, both for DC
vaccination10,17,18 and for peptide vaccination,5 we
decided to add a second LAA in order to broaden
anti-leukaemic responses and to decrease the
possibility of immune escape. We chose PRAME as
the most prominent cancer–testis antigen in
AML.19,20 CMVpp65 as a very abundant and
immunogenic viral antigen was added for loading
of a third batch of DCs, allowing us to differentiate
between the induction of primary and secondary
immune responses by comparison of CMV-
seronegative and CMV-seropositive patients.
The primary objective of this trial using next-
generation DCs for post-remission therapy of AML
patients was to explore the feasibility of DC
generation as well as the safety of the
Figure 5. Survival analysis. OS (a, c, e) and RFS (b, d, f) of the vaccinated patients were depicted by Kaplan–Meier plots and compared by the
log-rank test. (a, b) Patients treated within the trial were compared to a closely matched cohort of 88 patients from the AML-CG registry. (c, d)
Within the study cohort, patients ≤ 65 years and > 65 years at time of diagnosis were compared. (e, f) Immune responders as defined by an
increase in LAA-specific T cells after vaccination were compared to immune non-responders.
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vaccinations. Patients in first CR after intensive
chemotherapy, but with a high risk of relapse,
could be included. Three of the 13 patients who
were enrolled did not proceed to vaccination
because of disease-related factors (very early
relapse prior to the first vaccination; n = 2) or
because of factors related to vaccine production
(high IL-10 secretion by DCs; n = 1). The high
production of IL-10 by the DC vaccine produced
for patient #8 was unique and had never been
seen before in preclinical experiments. This
accentuates both the very high relapse risk of the
enrolled patients and the high success rate
(> 90%) in production of DCs secreting high
amounts of IL-12p70 and low amounts of IL-10.
For the other 10 patients, the generated DCs
sufficed for vaccination of all three antigens at
the minimum of six specified time points.
Median time between leukapheresis and start of
the vaccination was 25 days (Supplementary
table 1). Eight of these 10 patients completed
the full study protocol, while two were taken
off study because of early relapse, again
highlighting the unfavorable prognosis of the
included patients. We conclude that generation
and administration of next-generation DCs are
feasible in AML patients after intensive
chemotherapy, albeit early relapse can prevent
successful administration in very high-risk
patients. Judging from the 105 vaccinations that
were administered in total, tolerability of the
protocol was excellent. Only transient adverse
events were observed, and except for one grade
3 pyrexia, all adverse events were graded 1–2
(Supplementary table 2). Despite using DCs with
stronger immunostimulatory capacity compared
to prior vaccination studies, our data showed an
excellent safety profile.
As a secondary objective of the trial, we studied
immunological responses to the DC vaccinations.
Antigen loading was done by electroporation of
mRNA in order to allow for HLA-independent,
multiple-epitope antigen presentation. T-cell
responses before and after the vaccinations were
detected by multimer staining and by ELISpot. The
analysis of CMVpp65-specific T-cell responses
allowed us to distinguish between T- and B-cell
responses in latent CMV carriers in comparison with
CMV negative patients. Within our cohort, 3/10
patients were seropositive for antibodies against
human CMV. Before the vaccinations, we detected
antigen-specific T cells by tetramer and ELISpot in
all three seropositive patients (Table 2).
Interestingly, we observed an induction of a T-cell
response to CMVpp65 in all but one patient after
vaccination, and an expansion of CMVpp65-specific
T cells in seropositive patients. For one patient (#1),
we observed divergent results between ELISpot and
multimer assays, with strong upregulation of the
ELISpot response and downregulation of the
multimer-positive population. We hypothesise that
this might be interpreted as a selective expansion of
antigen-specific T cells not detected by the available
multimers or possible determinant spreading to T
cells recognising an alternative epitope. Using major
histocompatibility complex (MHC) class II multimers,
we found an increase in antigen-specific CD4+ T
cells in four of seven applicable patients (Table 2).
In two of these patients (#7, #10), this correlated
with development of antibodies against CMVpp65.
A physiological seroconversion as a result of primary
CMV infection was ruled out by missing detection
of the CMV-associated protein p150. From the data
on CMVpp65 immunomonitoring, we conclude that
next-generation DCs are capable of inducing
primary and secondary immune responses.
These are not restricted to CD8+ T-cell responses,
but also comprise CD4+ T-cell and antibody
responses.
Similarly, we were able to show the induction of
LAA-specific T-cell responses. However, in contrast
to the immune responses against CMVpp65, the
responses directed against WT1 and PRAME were
lower in frequency and not detected in all patients.
This might partially be attributed to restricted
availability of HLA-specific multimers and a random
mix of peptides with different lengths for the
ELISpot assays. Therefore, it is likely that not all
LAA-specific T cells were detected in spite of the
two complementary methods. However, differences
between a viral antigen and autoantigens certainly
play a role, with high-affinity T cells against the
latter being negatively selected in the thymus
during T-cell development. Our immunomonitoring
data provide evidence that the immunostimulatory
capacity of next-generation TLR7/8-matured DCs is
very high. Further work is needed to identify the
optimal setting for DC application, for example
induction of neoantigen-specific T cells or boosting
of genetically engineered T cells for adoptive
transfer.
In spite of the single-arm phase I design and
the limited patient number in this first-in-human
trial, we believe it is highly relevant to report
the safety and tolerability of a TLR7/8-matured
DC vaccine. The successful application of more
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than 100 vaccines demonstrates the suitability of
the vaccine, which is also applicable in other
cancer entities. Besides, we demonstrated the
induction of immunological responses.
Promising clinical outcome is suggested by the
comparison to a closely matched patient cohort.
A beneficial effect of vaccination was observed
with respect to RFS with a median survival of
1084 compared to 396 days. This effect was
more pronounced for patients of younger age
and with vaccine-induced immune responses.
Patients ≤ 65 years showed significantly better
OS and RFS than patients > 65 years. Two of the
patients in the older cohort relapsed quickly
without detection of a LAA-specific immune
response, and the third patient relapsed shortly
after termination of the vaccination protocol. In
the younger cohort, however, only two of seven
patients relapsed, and six of seven were still
alive at data cut-off. This is in line with a recent
publication, in which an overall survival benefit
was dominantly observed in the patient cohort
below 65 years of age.10 This might be related
to the larger pool of naive T cells in younger
AML patients, which are required for the
induction of novel anti-leukaemic immune
responses.21 Moreover, immune responses
against WT1 and PRAME correlated to
prolonged OS and RFS (Figure 5e and f).
Specifically, all three patients of the younger
age group that showed a leukaemia-specific
immune response remained in ongoing CR until
data cut-off. Our data support the hypothesis
that TLR7/8-matured DCs induce protective LAA-
specific immune response in patients ≤ 65 years.
However, frequency and strength of LAA-
specific immune responses need to be enhanced
in order to improve clinical benefit.
Of note, because of the very small patient
number, the comparison of survival data with the
matched patient cohort is purely exploratory and
hypothesis-generating. There was therefore no
formal statistical analysis plan for this comparison,
and multiple testing was not compensated for.
Several factors might have contributed to the
fact that the immunological and clinical effects in
this study were lower than might have been
expected. The use of autoantigens for vaccination
has been discussed above. Second, a comparison
of the DC characterisation within this trial with
the results of our preclinical experiments12,13,15
showed considerably lower CD86/PD-L1 ratio and
IL-12p70 secretion. This might be due to the
upscaling of the DC generation process including
elutriation of a leukapheresis product after
overnight storage instead of plastic adherence of
freshly isolated PBMCs.
However, we believe that combinatorial
approaches are the most promising strategy to
further enhance immune responses and hence
clinical benefit. Epigenetic modifiers such as DNA
methyltransferase inhibitors and histone
deacetylase inhibitors are suitable combination
partners because of an enhancement in antigen
processing and presentation of malignant cells.22–25
In the setting of myelodysplastic syndrome, the
combination of vaccination against NY-ESO-1 and
decitabine resulted in an increased antigen-specific
immune response.26 In our hands, the combination
of next-generation DC vaccination with 5-
azacytidine resulted in a striking increase in local
and systemic immune responses. This translated
into a temporary MRD conversion in a single
patient. We suggest pursuing this approach in
further clinical trials. Immune checkpoint blockade
is another strategy for combinational approaches.
Early clinical trials are already combining vaccines
with programmed cell death protein 1 (PD-1)
blockers for treatment of various malignancies
including AML.27 The combination of both
epigenetic modification by azacytidine and PD-1
blockade by nivolumab was recently shown to be a
safe and effective therapy for relapsed AML.28
However, other checkpoint molecules might be
even more relevant as suggested by our preclinical
data showing that blockade of lymphocyte
activation gene 3 (LAG-3) strongly enhances DC-
induced immune responses against viral and
leukaemia-associated antigens.29
CONCLUSIONS
Vaccination of high-risk AML patients with TLR7/
8-matured RNA-loaded DCs was feasible, safe and
resulted in induction of leukaemia-specific
immune responses. Explorative comparison to a
matched cohort suggests a benefit on the clinical
outcome; positive effects of vaccination on
survival were particularly seen for immune
responders and patients ≤ 65 years. Perspectively,
immune responses can be further augmented by
combining TLR7/8-matured DCs with
immunomodulatory drugs like hypomethylating
agents or checkpoint inhibitors.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
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METHODS
Study design
We here report results of a phase I trial, with clinical efficacy
analysis being purely explorative. AML (excluding acute
promyelocytic leukaemia) patients at the age of 18–75 with
a non-favorable risk profile (intermediate I, intermediate II
or adverse according to European LeukemiaNet (ELN)
classification of 2010;30 or with a favorable risk according to
ELN and MRD positivity) in CR/CRi after at least one cycle of
intensive induction therapy including an anthracycline and
cytarabine were eligible for enrolment. Patients with prior
allo-HSCT, severe organ dysfunction or active clinically
relevant autoimmune disease were excluded. None of the
patients were eligible for an allo-HSCT, either because of
comorbidities, lack of donor or missing consent. The primary
objective of the study was to determine safety and
feasibility of immunotherapy with autologous DCs, resulting
in the endpoints of frequency of adverse events and
percentage of patients in whom treatment with the
scheduled number of immunotherapies (10 DC vaccinations)
was feasible. As a secondary objective, we explored the
induction of immunological responses to the DC vaccination.
Clinical responses were estimated by comparing RFS and OS
between immune responders and non-responders as well as
between all vaccinated study patients and matched control
patients of the AML-CG registry. The vaccine was
administered intradermally up to 10 times within 26 weeks
at 5 9 106 DCs for each antigen (three batches at three
separate sites) and time point, starting at weekly intervals
and continuing at four-week intervals (see Supplementary
figure 5). No other anti-leukaemia therapy was permitted in
parallel as long as the patient was in remission, but 5-
azacytidine was added to the ongoing vaccination strategy
in some patients when the criteria for a leukaemia relapse
were met. The study was mono-centric, open-label,
prospective and non-randomised. All patients with successful
vaccine generation who still met the eligibility criteria after
this process were vaccinated at the Department of Medicine
III, University Hospital, LMU Munich.
Vaccine generation
Peripheral blood mononuclear cells were collected by
leukapheresis and transported to the GMP facility of the
Department of Cellular Therapy at The Norwegian Radium
Hospital in Oslo. Monocytes were enriched from
leukapheresis using elutriation (ELUTRA, Caridian) and
cultured in RPMI 1640 medium with very low endotoxin
(Biochrom, Berlin, Germany) plus 1.5% human AB serum
(Institute of Transfusion Medicine, Suhl, Germany),
supplemented with 560 IU mL!1 GM-CSF (Leukine!, Bayer,
Leverkusen, Germany) and 20 ng mL!1 interleukin-4 (R&D
Systems, Wiesbaden, Germany) for 40–72 h. Thereafter,
10 ng mL!1 TNF-a, 10 ng mL!1 IL1-b (both R&D Systems,
Wiesbaden, Germany), 5000 IU mL!1 interferon-c (Imukin!,
Boehringer Ingelheim, Ingelheim, Germany), 250 ng mL!1
PGE2 (Prostine! E2; Pfizer, Kent, UK) and 1 lg mL!1 R848
(3M Pharmaceuticals, St. Paul, MN, USA) were added to the
culture medium for another 20–26 h.16 Mature DCs were
thoroughly washed and electroporated in three different
batches, each transduced with in vitro transcribed (ivt)
codon-optimised RNA (produced at Oslo University Hospital
in clinical grade) encoding for either human WT1 (isoform
A, NP_000369.3), PRAME (NP_006106.1) or CMVpp65
(P06725.2). After 2–6 h, DCs were harvested and
cryopreserved. Before the first batch of DCs was
administered to the individual patient, release criteria
including total cell number, viability, and CD80 positivity, as
well as lack of excessive contaminating cells, microbiological
contamination and mycoplasma, were controlled (see
Supplementary table 5 for details). Before administration,
cells were resuspended with 200 µL DPBS each.
Vaccine characterisation
Expression of DC surface antigens was measured by flow
cytometry using a panel of fluorescence-conjugated
monoclonal antibodies (Supplementary table 6). Dead cells
were excluded by Live/Dead Aqua (Invitrogen, Carlsbad, CA,
USA) staining and only singlets gated. Corresponding
mouse IgG isotype controls were used. After washing, cells
were analysed using a FACS LSR II (BD Biosciences). Post-
acquisition analysis was performed using FlowJo software
(version 9.7.6; Tree Star, Ashland, OR, USA). The percentage
of positive cells was determined by setting the gate at or
below 1% in the respective isotype control. SFI was
calculated as the ratio of the median fluorescence intensity
of the test sample to its corresponding isotype control.
Migration and cytokine secretion capacity of DCs were
analysed as described previously.14 To assess protein
expression of transfected RNA in DCs, the freshly thawed
cells were fixed using Foxp3 Staining Buffer Set
(eBioscience). After FcR blocking, intracellular antigen
staining was performed with anti-HCMV, anti-WT1 or anti-
PRAME, and AF647-conjugated anti-mouse F(ab)2 as
secondary antibody (Supplementary table 6). DC antigen
presentation capacity was tested in an human leucocyte
antigen (HLA)-matched 24h coculture of CMVpp65, WT1 or
PRAME RNA-transfected DCs with CMV-specific T cells
(kindly provided by A. Moosmann), WT1-specific T cells
(generated in our laboratory as previously described31) or
PRAME-specific T cells (generated as previously described32),
respectively, at a 1:10 ratio. IFN-c secretion into the
supernatant was analysed by cytometric bead array (CBA)
Human IFN-c Flex Set (BD Biosciences).
Measurement of immune responses
Local reactions at the vaccine sites were assessed by
measuring the diameter of the erythema 48h after the
fifth vaccination. Skin biopsies were taken and analysed
by immunohistochemistry for CD4+ and CD8+ T-cell
infiltration. Patients’ lymphocyte subpopulations in
peripheral blood were analysed according to standard
procedures. Human IFN-c single-colour ELISpot assays
(CTL, Bonn, Germany) were performed following the
manufacturer’s recommendations with 2µg mL!1
CMVpp65, WT1 or PRAME peptide pools (JPT, Berlin,
Germany) in triplicates. Resulting spots were counted
using the ImmunoSpot S6 Analyzer’s (CTL) Smart Count
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Mode. Multimer staining was performed depending on
the patient’s HLA (Supplementary table 4) and availability
of corresponding multimers. PE-labelled multimers
(Supplementary table 6) were used for identification of
vaccine-induced CD4+ and CD8+ T cells specific for
CMVpp65, WT1 and PRAME. Multimers for HIV-Gag and
CLIP were used as controls. For detection of CMV-specific
CD4+ T cells by MHC class II multimers, PBMCs were
expanded for 7 days in the presence of 2.5 µM CMVpp65
peptide EPDVYYTSAFVFPTK (JPT) with 5 ng mL!1 IL-7 und
IL-15 (PeproTech) added during the last three days. T-cell
surfaces were additionally stained for CD3, CD4 and CD8.
Patient sera were analysed for antibodies against the
single antigens of human CMV before and after
vaccination using the recomLine CMV IgG, IgM
Immunoassay (MIKROGEN, Neuried, Germany) and the
Enzygnost! (Siemens Healthcare GmbH, Erlangen,
Germany). Primary CMV infection during the trial was
excluded by assessment of the study-specific p65 protein
without concomitant detection of the p150 protein.
Clinical assessments
Patients were monitored for adverse events starting from
the first screening visit until 4 weeks after the last
vaccination. All toxicities were graded according to the
National Cancer Institute Common Toxicity Criteria version
5.0. Leukaemia was assessed by routine bone marrow
diagnostics including determination of MRD by available
molecular markers and by LAIP. RFS and OS were followed
until the cut-off date of 31 March 2018 and depicted by
swimmer plot for individual patients and by Kaplan–Meier
plots.
Statistical analysis
For the analysis of ELISpot responses, the frequency of
antigen-specific T cells was calculated by subtracting the
mean number of spots in the control wells from the mean
number of spots observed in response to antigen. Prior to
the vaccination, ≥ 5 antigen-specific T cells were considered
a positive response (+ in Table 2) and ≥ 100 antigen-specific
T cells were considered a highly positive response (++).
Upregulation of an immune response to the vaccinations (↑)
was defined to be a ≥ 1.5-fold increase of antigen-specific
spot count and ≥ 5 antigen-specific T cells after
vaccinations. For determination of antigen-specific T cells by
multimer staining, the percentage of CD8+ or CD4+ T cells
stained positive with a control multimer was subtracted
from the percentage of cells stained positive with the
specific multimer. Prior to the vaccination, ≥ 0.1% antigen-
specific T cells were considered a positive response (+ in
Table 2) and ≥ 1% antigen-specific T cells were considered a
highly positive response (++). Upregulation of an immune
response to the vaccinations (↑) was defined to be a ≥ 2-
fold increase of multimer-positive CD8+ or CD4+ T cells and
≥ 0.1% antigen-specific T cells after vaccinations.
Downregulation of an immune response to the vaccinations
(↓) was defined to be a ≥ 2-fold decrease of multimer-
positive CD8+ or CD4+ T cells. An immune response to a
specific antigen was defined by upregulation of the ELISpot
and/or multimer response to the respective antigen
(Table 2). In order to compare survival data of this single-
arm trial to that of AML patients with very similar
characteristics, a carefully matched cohort of 88 patients
from the AML-CG registry was selected according to the
following criteria: CR/CRi/CRp after intensive induction
therapy; no allo-HSCT in CR1; duration of remission at least
as long as in the trial population; non-favorable risk type;
ECOG 0 or 1; and age at diagnosis 18–75. A comparison of
patient characteristics between the DC study cohort and the
AML-CG registry cohort is depicted in Supplementary table
3. Differences in survival between different groups were
tested by log-rank test.
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Supplementary Materials: 
 
Supplementary figure 1. DC phenotype: Expression of surface molecules detected on DCs by 
flow cytometry in a representative patient sample. 
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Supplementary figure 2. DC antigen expression: Freshly thawed DCs were intracellularly 
stained for the proteins translated from the electroporated RNA. DCs electroporated with one of 
the other two RNA species (PRAME as control for WT-1, CMV as control for PRAME, and 
WT1 as control for CMVpp65) served as control. A representative patient sample is shown. 
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Supplementary figure 3. Immunmonitoring data for patients #1, #4, #6, and #10. PBMCs 
isolated before and after vaccination were tested for antigen-specific T cells (a) by Elispot and 
(b) by multimer staining.  
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Supplementary figure 4. Individual treatment attempt with combination of 5-azacytidine 
and DC vaccination in patient #1. (a) Course of LAIP and WT1 MRD, showing MRD relapse 
after 10 vaccinations and MRD conversion after the combination therapy. (b) Enhanced local 
reaction to the vaccination after preceding 5-azacytidine therapy. (c) Increase in WT1-specific T 
cells after the combination therapy as measured by multimer. 
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Supplementary table 1. Leukapheresis data. Leukocyte count and Monocytes refer to the 
patient’s peripheral blood values at the screening visit before leukapheresis. WBC = White blood 
cells and Monocyte yield refer to the leukapheresis product. Potential vaccinations = Number of 
sets of three batches each for vaccinations with DCs loaded with all three antigens. Vx1, First 
vaccination. 
Leukocyte count 
(GxL^-1) Monocytes (%)
WBC 
(x10^10)
Monocyte yield 
(x10^9)
DC recovery after 
electroporation (x10^8)
Potential
vaccinations
Leukapheresis to 
Vx1 (d) CR to Vx1 (d)
#1 7.6 11 1.4 3.4 3.76 14 24 82
#2 5.9 7 1 2.2 1.27 6 25 104
#3 2.3 7 0.8 2.7 3.96 14 n.a. n.a.
#4 3.7 11 1 3.4 5.45 22 32 149
#5 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
#6 10.5 4 1.7 5.1 5.68 25 24 176
#7 5.9 13 1.5 3.6 1.85 10 18 34
#8 9.4 6 2.7 7.5 2.86 10 n.a. n.a.
#9 4.1 10 1.1 3.6 3.39 14 25 97
#10 2.6 11 1.4 3.8 3.54 16 38 96
#11 5.19 7 0.9 3.9 4.84 24 25 116
#12 4.45 7 2.8 6.6 5.22 24 26 205
#13 3.26 9 0.6 1.0 2.38 11 19 185
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Supplementary table 2. Adverse events reported during the study. Listed are all adverse 
events that were observed in ≥ 2 patients and were at least possibly related to the investigational 
medicinal product. 
 
Adverse Event Grade n (% of n=10) 
Vaccine site reaction (erythema, 
induration, pruritus) 
1 10 (100) 
Musculoskeletal pain 1–2 6 (60) 
Skin reactions (erythema, 
pruritus) outside of vaccine sites 
1 5 (50) 
Diarrhea 1–2 4 (40) 
Fatigue 1 4 (40) 
Headache 1–2 3 (30) 
Vertigo 1–2 3 (30) 
Arthralgia 1 3 (30) 
Cough 1 3 (30)  
Nausea and vomiting 1 3 (30) 
Respiratory infection 1 3 (30) 
Night sweats 1 2 (20) 
Pyrexia 1, 3 2 (20) 	
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Supplementary table 3. Patient characteristics of the trial cohort in comparison with the 
matched cohort from the AML-CG registry. 
 
DC study cohort AML-CG cohort
No. of patients 13 88
Age, years
Median (range) 62 (44-79) 62 (25-75)
Patients age, N (%)
 ≤ 65 years
 > 65 years
9 (69)
4 (31)
52 (59)
36 (41)
Sex Female/male, N (%) 4/9 (31/69) 40/48 (45/55)
ECOG, N (%)
0
1
2
2 (15)
10 (77)
1 (8)
24 (27)
64 (73)
0 (0)
ELN, N (%)
Favorable
IntermediateI
intermediateII
Adverse
2 (15)
7 (54)
3 (23)
1 (8)
0 (0)
42 (48) 
30 (34)
16 (18)
Molecular aberrations, N (%):
NPM1 mutation
Pos.
Neg.
Missing/unknown
1 (8)
11 (92)
1
28 (35)
53 (65)
7
FLT3-ITD
Pos.
Neg.
Missing/unknown
3 (33)
6 (67)
4
23 (28)
58 (72)
7
FAB, N (%)
M0
M1
M2
M3
M4
M5
M6
M7
s-AML (MDS)
Missing/unknown
2 (15)
5 (38)
2 (15)
0 (0)
1 (8)
0 (0)
0 (0)
0 (0)
3 (23)
0
7 (9)
18 (22)
23 (28)
0 (0)
13 (16)
10 (12)
0 (0)
1 (1)
9 (11)
7 
Leukocytes at dx (GxL^-1)
Median (range) 3 (1-94) 8 (1-292)
LDH, UxL^-1
Median (range) 232 (181-2401) 388 (63-8078)
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Supplementary table 4. HLA-typing of the patients. Multimer staining was performed against 
the HLAs highlighted in bold with corresponding multimers. 
 
 
 
A B C DRB1 DQB1 DPB1
#1 24:02, 
 30:01 
07:02, 
13:02 
06:02, 
07:02 
07:01, 
15:01 
02:02, 
06:02 
04:01, 
04:02 
#2 02:01, 
 03:01 
44:05, 
56:01 
01:02, 
02:02 
07:01, 
16:01 
05:02, 
03:03 
04:01, 
10:01 
#3 02:01, 
 24:02 
14:01, 
40:01 
03:04, 
08:02 
07:01 02:02, 
03:03 
04:01 
#4 03:01, 
 23:01 
07:02, 
44:03 
04:01, 
07:02 
07:01, 
15:01 
02:02, 
06:02 
04:01 
#5 02:01, 
 03:01 
07:02 07:02 15:01 06:02 02:01, 
04:01 
#6 02:01  15:01, 
18:01 
03:04, 
07:01 
04:01, 
14:54 
03:02, 
05:03 
04:01 
#7 03:01, 
 25:01 
13:02, 
18:01 
06:02, 
12:03 
07:01, 
15:01 
02:02, 
06:02 
03:01, 
04:01 
#8 01:01, 
 03:01 
08:01, 
40:01 
07:01, 
15:02 
08:01, 
15:01 
04:02, 
06:02
04:01, 
04:02
#9 03:01, 
 26:08 
15:01, 
40:01 
03:04, 
04:01 
01:01, 
11:03
03:01, 
05:01 
03:01, 
04:02
#10 01:01 49:01, 
57:01 
06:02, 
07:22 
07:01, 
13:02
03:03, 
06:04 
02:01, 
04:01
#11 02:01, 
 32:01 
44:02, 
51:01
05:01, 
15:02 
07:01, 
11:01 
03:01, 
03:03 
03:01, 
04:01
#12 01:01, 
 31:01 
27:05, 
39:01 
01:02, 
12:03 
07:01, 
13:01 
02:02, 
06:03 
04:01 
#13 11:01, 
 24:02 
07:02, 
27:05 
02:02, 
07:02 
13:01, 
15:01 
06:02, 
06:03 
03:01, 
04:02 
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Supplementary table 5. Release Criteria for the DC vaccine. 
 
Parameter Method Specification
Total cell count in 
500 µL
Cell Dyn Ruby (Abott) >  2x10^6
Viability Tryphan blue (Ph. Eur.) > 60%
CD80 positive Flow Cytometry (BD) > 60%
Microbiological 
contamination
Bactec System (BD) Negative
Contaminating cells 
(NK, T and B cells)
Flow Cytometry (BD) < 20%
Mycoplasma testing 16SrDNA PCR and sequencing Negative
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Supplementary table 6. List of antibodies and primers used in the study. 
Reagent Manufacturer City, Country
Antibodies anti-CD14 (FITC, 61D3) eBioscience San Diego, CA, USA
anti-CD40 (PE, clone 5C3) eBioscience San Diego, CA, USA
anti-CD80 (PE, L307.4) BD Biosciences Heidelberg, Germany
anti-CD83 (APC, HB15) BD Biosciences Heidelberg, Germany
anti-CD86 (PB, IT2.2) BioLegend San Diego, CA, USA
anti-CD274 (FITC, MIH1) BD Biosciences Heidelberg, Germany
anti-CCR7 (APC, FR11-11E8) Miltenyi Biotec Bergisch Gladbach, Germany
anti-HLA-DR (PE, LN3) BioLegend San Diego, CA, USA
anti-CD3 (APC, UCHT1) BioLegend San Diego, CA, USA
anti-CD4 (FITC, VIT4) Miltenyi Biotec Bergisch Gladbach, Germany
anti-CD8 (PerCP-eFluor710, SK1) eBioscience San Diego, CA, USA
Live/Dead Aqua Invitrogen Carlsbad, CA, USA
FcR Blocking Reagent Miltenyi Biotec Bergisch Gladbach, Germany
anti-HCMV ppUL83   Biomerieux Marcy-l’Étoile, France
anti-WT1 (6F-H2) Agilent Santa Clara, CA, USA
anti-PRAME (ab89097) Abcam Cambridge, UK
AF647-conjugated anti-mouse F(ab)2  Dianova Hamburg, Germany
CMVpp65 (A*01:01-YSEHPTFTSQY) ProImmune Oxford, UK
CMVpp65 (A*02:01-NLVPMVATV) Immudex Copenhagen, Denmark
CMVpp65 (A*24:02-QYDPVAALF) Immudex Copenhagen, Denmark
CMVpp65 (B*07:02- TPRVTGGGAM) Immudex Copenhagen, Denmark
CMVpp65 (DRB1*07:01-EPDVYYTSAFVFPTK) NIH Tetramer Facility Atlanta, GA, USA
WT1 (A*02:01-RMFPNAPYL) Immudex Copenhagen, Denmark
WT1 (A*02:01-VLDFAPPGA)  Immudex Copenhagen, Denmark
WT1 (A*24:02-CYTWNQMNL) Immudex Copenhagen, Denmark
WT1 (B*07:02- RQRPHPGAL) Immudex Copenhagen, Denmark
PRAME (A*02:01-VLDGLDVLL) Immudex Copenhagen, Denmark
PRAME (A*02:01-ALYVDSLFFL) Immudex Copenhagen, Denmark
HIV-Gag (A*02:01-SLYNTVATL) Immudex Copenhagen, Denmark
HIV-Gag (A*24:02-RYLKDQQLL) Immudex Copenhagen, Denmark
HIV-Gag (B*07:02-GPGHKARVL) Immudex Copenhagen, Denmark
CLIP (DRB1*07:01-PVSKMRMATPLLMQA) NIH Tetramer Facility Atlanta, GA, USA
Primer Roche FastStart Essential DNA Probes Master 
(# 06402682001)
Roche Diagnostics Basel, Switzerland
Real time ready singe Assays - Roche PRAME 
Assay ID: 117436, config. # 100104279
Roche Diagnostics Basel, Switzerland
Real time ready singe Assays - Roche Abl1 Assay 
ID: 144473, config. # 100104288
Roche Diagnostics Basel, Switzerland
WT1 forward primer 5´-cgctattcgcaatcagggtta-3´ MetaBion International AG Martinsried, Germany
WT1 reverse primer 5´-gggcgtgtgaccgtagct-3´ MetaBion International AG Martinsried, Germany
WT1 probe  5´-FAM-agcacggtcaccttcgacgg-BHQ-1-3´ MetaBion International AG Martinsried, Germany
cABL Taq forward primer 5´-cct ttt cgt tgc act gta 
tga ttt-3´ 
MetaBion International AG Martinsried, Germany
cABL Taq reverse primer 5´-cgcc taa gac ccg gag 
ctt tt-3´ 
MetaBion International AG Martinsried, Germany
ABL1 probe  5´-FAM-tgg cca gtg gag ata aca ctc 
taa gca taa cta aag g-BHQ-1-3´ 
MetaBion International AG Martinsried, Germany
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Targeting LAG-3 and PD-1 to 
Enhance T Cell Activation by 
Antigen-Presenting Cells
Felix S. Lichtenegger1,2†, Maurine Rothe1,2†, Frauke M. Schnorfeil1,2,3 , Katrin Deiser1,2, 
Christina Krupka1,2, Christian Augsberger1,2, Miriam Schlüter1,2, Julia Neitz1,2 and Marion 
Subklewe1,2,3 *
1 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany, 2 Laboratory for Translational Cancer 
Immunology, Gene Center, LMU Munich, Munich, Germany, 3 German Cancer Consortium (DKTK) and German Cancer 
Research Center (DKFZ), Heidelberg, Germany
Immune checkpoint inhibition has been shown to successfully reactivate endogenous 
T  cell responses directed against tumor-associated antigens, resulting in significantly 
prolonged overall survival in patients with various tumor entities. For malignancies with 
low endogenous immune responses, this approach has not shown a clear clinical benefit 
so far. Therapeutic vaccination, particularly dendritic cell (DC) vaccination, is a strategy to 
induce T cell responses. Interaction of DCs and T cells is dependent on receptor–ligand 
interactions of various immune checkpoints. In this study, we analyzed the influence of 
blocking antibodies targeting programmed cell death protein 1 (PD-1), HVEM, CD244, 
TIM-3, and lymphocyte activation gene 3 (LAG-3) on the proliferation and cytokine 
secretion of T  cells after stimulation with autologous TLR-matured DCs. In this con-
text, we found that LAG-3 blockade resulted in superior T cell activation compared to 
inhibition of other pathways, including PD-1/PD-L1. This result was consistent across 
different methods to measure T cell stimulation (proliferation, IFN-γ secretion), various 
stimulatory antigens (viral and bacterial peptide pool, specific viral antigen, specific tumor 
antigen), and seen for both CD4+ and CD8+ T cells. Only under conditions with a weak 
antigenic stimulus, particularly when combining antigen presentation by peripheral blood 
mononuclear cells with low concentrations of peptides, we observed the highest T cell 
stimulation with dual blockade of LAG-3 and PD-1 blockade. We conclude that priming 
of novel immune responses can be strongly enhanced by blockade of LAG-3 or dual 
blockade of LAG-3 and PD-1, depending on the strength of the antigenic stimulus.
Keywords: cancer immunotherapy, dendritic cell, immune checkpoint molecules, LAG-3, PD-1, T cell response
Abbreviations: AML, acute myeloid leukemia; APC, antigen-presenting cell; CBA, cytometric bead array; CEFT, CMV, EBV, 
influenza, tetanus; CFSE, carboxyfluorescein N-succinimidyl ester; DC, dendritic cell; FLR, Epstein–Barr nuclear Ag 3 A 
peptide FLRGRAYGL; HD, healthy donor; LAG-3, lymphocyte activation gene 3; MACS, magnetic activated cell sorting; MFI, 
median fluorescence intensity; MHC, major histocompatibility complex; NAC, non-adherent cell; PB, peripheral blood; PBMC, 
peripheral blood mononuclear cell; PD-1, programmed cell death protein 1; PRAME, preferentially expressed antigen in 
melanoma; ORR, objective response rate; TCM, central memory T cell; TEM, effector memory T cell; TEMRA, effector memory RA 
T cell; Tnaive, naive T cell; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; TLR, toll-like receptor; TLR-3-DCs, 
dendritic cells generated within 3 days based on a TLR7/8 ligand; VLD, WT1 peptide VLDFAPPGA; WT1, Wilms Tumor 1.
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INTRODUCTION
Immunotherapy has changed our approach to anti-cancer treat-
ment in recent years. Checkpoint inhibitors have particularly been 
in the focus of clinical development and have shown remarkable 
success as monotherapy or as combination partners for various 
tumor entities. This has resulted in approval for different solid 
tumor entities, but also for Hodgkin lymphoma (1–4). Checkpoint 
blockade is thought to reactivate endogenous T  cell responses 
directed against tumor neoantigens presented in the context of 
major histocompatibility complex (MHC) molecules. In tumors 
with low endogenous T cell responses, however, the primary goal 
of immunotherapy needs to be the initiation of T cell responses 
directed against tumor-associated antigens. Various vaccination 
concepts are being pursued, and only recently, personalized 
neoantigen-based vaccines were shown to efficiently trigger T cell 
responses and lead to improved clinical outcome in patients with 
malignant melanoma (5, 6).
Dendritic cells (DCs) are particularly eligible to induce strong 
and durable immune responses. Over the years, multiple differ-
ent maturation protocols have been used to generate DCs from 
monocytes ex vivo (7), and the resulting DCs differ considerably 
in their immunostimulatory capacities. We have developed a 
GMP-compliant 3-day protocol for the generation of DCs with 
improved immunogenicity based on a toll-like receptor (TLR) 
7/8 ligand (TLR-3-DCs) (8). These DCs express higher numbers 
of co-stimulatory molecules and secrete higher levels of IL-12p70 
compared to DCs generated with the standard protocol (9). 
Currently, we are conducting a phase I/II study on vaccination 
with DCs loaded with Wilms Tumor 1 (WT1) and preferentially 
expressed antigen in melanoma as leukemia-associated antigens 
for postremission therapy of acute myeloid leukemia (AML) 
patients (10).
In order to further enhance immunological and clinical 
responses, multiple combinatorial approaches with DC vaccina-
tion can be considered. These include, but are not restricted to 
chemotherapy and radiotherapy, cytokines and TLR agonists, 
hypomethylating agents, but also more targeted strategies, such 
as elimination of immunosuppressive cell types (e.g., myeloid-
derived suppressor cells, regulatory T cells), molecularly targeted 
therapies and adoptive cell therapy (11, 12).
Another promising approach is the combination of DC vac-
cination with immune checkpoint inhibitors (13). Activated or 
chronically stimulated T  cells upregulate various co-inhibitory 
molecules, such as programmed cell death protein 1 (PD-1), 
CD244 (2B4), CD160, T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3, CD366), and lymphocyte activation gene 3 
(LAG-3, CD223) (14, 15). Their ligands are expressed both on 
antigen-presenting cells (APCs) and tumor cells. The inhibition 
of these checkpoints by blocking antibodies can, thus, enhance a 
vaccination-induced anti-cancer immune response in two ways. 
On the one hand, checkpoint inhibitors influence the interaction 
between T  cells and cancer cells, resulting in enhanced anti-
cancer T cell responses. On the other hand, checkpoint blockade 
may enhance the antigen-specific activation of T cells by DCs or 
other APCs. Studies performed in this field so far mainly focus on 
the inhibition of the PD-1/PD-L1 pathway (16–21).
Other co-inhibitory molecules, however, are also expressed on 
APCs, even on DCs after maturation with a TLR ligand (9). We, 
therefore, analyzed the effects of blocking various immune check-
points on the stimulation of T cells by autologous TLR-3-DCs, 
mainly using virus antigens as a model system. Besides PD-1, we 
tested HVEM, CD244, TIM-3, and particularly LAG-3.
LAG-3 is a member of the Ig superfamily that was identified in 
1990 (22). It is structurally similar to CD4 and binds MHC class 
II with a higher affinity than CD4 (23, 24). LAG-3 is expressed 
on activated CD4+ and CD8+ T  cells as well as on a subset of 
natural killer cells (22). By using a knock-out mouse model, 
LAG-3 was found to impede T cell expansion and to control the 
number of memory T  cells (25). Besides effector cells, LAG-3 
can also be found on the surface of T regulatory cells and seems 
to be instrumental for their suppressive activity (26) as well as 
for T cell homeostasis (27). Finally, LAG-3 is also expressed on 
plasmacytoid DCs (28). Thus, modulation of the LAG-3 pathway 
has the potential to impact autoimmunity and infections as well 
as cancer (29, 30). In three distinct transplantable tumor models, 
LAG-3 and PD-1 have been shown to be co-expressed on tumor-
infiltrating lymphocytes, and blockade of both pathways had 
synergistic effects on the anti-tumor CD8+ T cell response (31). 
Similarly in ovarian cancer patients, co-expression of LAG-3 and 
PD-1 was found on antigen-specific CD8+ T cells, and co-blockade 
of both lead to improved proliferation and cytokine production 
(32). Accordingly, different LAG-3 antibodies as monotherapy 
or in combination with anti-PD-1 have entered clinical trials for 
various cancer entities focusing on solid tumors.
In our model, we found that priming of T  cells by DCs is 
significantly enhanced by blockade of LAG-3. We, therefore, 
propose the combination of DC vaccination and LAG-3 block-
ade as a promising approach for the initiation of novel immune 
responses, particularly in tumors with low endogenous immune 
responses including AML.
MATERIALS AND METHODS
Media and Reagents
Very low endotoxin RPMI 1640 medium (FG 1415; Biochrom) 
supplemented with 1.5% human serum (serum pool of AB posi-
tive adult males; Institute for Transfusion Medicine)—hereafter 
named DC medium—was used for the generation of DCs and all 
coculture experiments. The following reagents were used to gen-
erate DCs: GM-CSF (300-03), rhIL-4 (200-04), IFN-γ (300-02; all 
PeproTech), rhIL-1β (201-LB), TNF-α (210-TA/CF; both R&D 
Systems), PGE2 (P5640; Sigma-Aldrich), and R848 (tlrl-r848; 
InvivoGen).
Cell Isolation and Generation of DCs
After written informed consent, peripheral blood (PB) samples 
were collected from healthy donors (HDs) under a clinical proto-
col entitled “in vitro studies to establish new immunotherapies for 
AML and other hematological neoplasias.” Both the consent form 
and the protocol were approved by the institutional review board 
(Ethikkommission bei der LMU München). Both cell isolation 
and generation of DCs were performed as described previously 
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for TLR-3-DCs (9) with the exception of polyI:C, which was not 
included in the maturation cocktail.
Coculture of DCs and T Cells
Dendritic cells were pulsed with a mixed CMV, EBV, influenza, 
and tetanus (CEFT) peptide pool (2 µg/ml; PM-CEFT; JPT) for 
2 h at 37°C, 5% CO2, incubated for 10 min on ice and subse-
quently washed. CD3+ T  cells were isolated from autologous 
non-adherent cells (NACs) by magnetic activated cell sorting 
(MACS, 130-050-101; Miltenyi Biotec) according to the manu-
facturer’s protocol. CEFT-pulsed DCs and CD3+ T  cells were 
cocultured at a ratio of 1:10 in 96-well round bottom plates 
for 4 days at 37°C, 5% CO2. For blocking experiments, the fol-
lowing monoclonal blocking antibodies were added at 10 µg/
ml: α-CD244 (PP35; 16-2449-81; eBioscience), α-HVEM (122; 
318802), α-TIM-3 (F38-2E2; 345003), α-PD-1 (EH12.27H7; 
329911; all BioLegend), α-LAG-3 (17B4; AG-20B-0012PF; 
AdipoGen or ab40466; Abcam). The blocking antibody concen-
tration of 10 µg/ml that we used was based on prior experiments 
demonstrating antibody blockade of immune checkpoints (21). 
Reducing the antibody concentration to 5 µg/ml did not alter our 
results (data not shown).
Coculture of DCs and NACs
Dendritic cells were pulsed with the Epstein–Barr nuclear Ag 3 A 
peptide FLRGRAYGL (FLR) (2 µg/ml; JPT) for 2 h at 37°C, 5% 
CO2 and subsequently washed. FLR-pulsed DCs and autologous 
NACs were cocultured at a ratio of 1:80 in 96-well round bottom 
plates for 6 days at 37°C, 5% CO2. For blocking experiments, α-
PD-1 and α-LAG-3 were added as above.
Culture of PBMCs
Peripheral blood mononuclear cells (PBMCs) were loaded with 
FLR and cultured in 96-well round bottom plates (5 × 105/well) 
in the presence or absence of α-PD-1 and α-LAG-3 for 6–8 days 
at 37°C, 5% CO2.
Surface Phenotyping of DCs and T Cells
Immunofluorescent staining of DC surface antigens was performed 
using a panel of fluorescence-conjugated monoclonal antibodies: 
CD80 (PE, L307.4; 560925), CD83 (APC, HB15e; 551073) CD86 
(FITC, 2331 (FUN-1); 557343), CD273 (APC, MIH18; 557926), 
CD274 (FITC, MIH1; 558065; all BD Biosciences), Galectin-9 (PE, 
9M1-3; 348906), CD48 (FITC, BJ40; 336706), HLA-DR (Pacific 
Blue, LN3; 327016; all BioLegend), HVEM (APC, 94801; FAB356A; 
R&D Systems). Corresponding isotype controls were used.
Immunofluorescent staining of T-cell surface antigens was per-
formed using the following fluorescence-conjugated monoclonal 
antibodies: CD244 (PE, C1.7; 329507 or APC, C1.7; 329511), 
PD-1 (Brilliant Violet 421, EH12.7H7; 329919), CD3 (FITC, 
UCHT1; 300406), CD45RA (Brilliant Violet 421, HI100; 304129; 
all BioLegend), CD160 (APC, 688327; FAB6700A), TIM-3 (PE, 
344823; FAB2365P; both R&D Systems), CD8 (PerCP-eFluor 710, 
SK1; 8046-0087; eBioscience), CD4 (APC-H7, RPA-T4; 560158; 
BD Biosciences), LAG-3 (ATTO 647N, 17B4; AG-20B-0012TS 
AdipoGen), CCR7 (CD197, APC, FR 11-11E8; 130-098-125; 
Miltenyi Biotec). Corresponding isotype controls were used. 
Intracellular FoxP3 staining was performed according to the 
manufacturer’s instructions (APC, 3G3; Miltenyi Biotec).
Cells were analyzed using a FACS LSR II (BD Biosciences). 
Post-acquisition analysis was performed using FlowJo software 
(version 9.7.6; Tree Star). The median fluorescence intensity 
(MFI) ratio was calculated by dividing the MFI of the measured 
population by the MFI of cells stained with the isotype-matched 
antibody. For the upregulation of checkpoint molecules, the 
percentage of positive cells (% positive) was obtained by setting 
the gate at or below 1% in the respective isotype control.
Cytokine Secretion Measurement by 
Bead-Based Immunoassay
Secretion of IFN-γ and TNF-α was quantified by cytometric bead 
array (CBA) Flex Set (560111; BD Biosciences) according to the 
manufacturer’s instructions.
CFSE Proliferation Assay
Isolated CD3+ T  cells were labeled with carboxyfluorescein 
N-succinimidyl ester (CFSE, C34554; Life Technologies) and 
cultured in the presence of autologous DCs. Unstimulated T cells 
served as negative control. Harvested cells were then stained 
with antibodies for CD3 (APC, UCHT1; 300412; BioLegend), 
CD4 (APC-H7), and CD8 (PerCP-eFluor 710). The percentage 
of divided cells (% divided) was analyzed using FlowJo software.
Fluorescence-Based Cell Sorting
Magnetic activated cell sorting-enriched CD3+ T cells were sorted 
according to CCR7 and CD45RA expression levels into naive 
T  cells (Tnaive), central memory T  cells (TCM), effector memory 
T cells (TEM), and effector memory RA T cells (TEMRA) using an 
Aria III (BD Biosciences).
Expansion of WT1 Peptide-Specific T Cells
Wilms Tumor 1 antigen VLD (VLD  =  WT1 peptide 
VLDFAPPGA)-specific T  cells were generated as previously 
described (33). Briefly, DCs were matured as described above. 
Autologous CD8+ T  cells were isolated from NACs using the 
CD8+ T Cell Isolation Kit (130-096-495; Miltenyi Biotec) and 
incubated overnight in VLE-RPMI medium supplemented with 
5% human serum and 5 ng/ml of IL-7 (200-07; Peprotech). DCs 
were pulsed with 2.5 µL/ml of the HLA-A*02:01-restricted VLD 
peptide (VLDFAPPGA; JPT) for 90  min and irradiated with 
30 Gy. CD8+ T cells and DCs were cocultivated in a 4:1 T cell:DC 
ratio and incubated with 30 ng/ml of IL-21 (200-21; Peprotech) 
in the presence or absence of 10 µg/ml LAG-3 or PD-1 block-
ing antibodies for 72  h. On day 3, cocultures were expanded 
1:1 by adding medium supplemented with 10 ng/ml IL-15 and 
IL-7 (200-07, 200-15; both Peprotech) and 10  µg/ml blocking 
antibodies. On days 6–7, cells were analyzed by flow cytometry 
using VLD multimer (WB3469; Immudex) and fluorescence-
conjugated monoclonal antibodies (see above).
Statistical Analysis
Data were analyzed using Prism 6 (GraphPad Software). All 
results are presented in box-and-whisker plots, with boxes 
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FIGURE 2 | Upregulation of immune checkpoint ligands on T cells after 
dendritic cell stimulation. T cells of 7–14 healthy donor were cocultured with 
autologous TLR-3-DCs pulsed with CMV, EBV, influenza, tetanus (CEFT) 
peptide pool or with CEFT peptide pool alone. Expression of various 
inhibitory checkpoint molecules was analyzed by flow cytometry. The 
percentage of positive cells is presented as box-and-whisker plots for CD4+ 
(A) and for CD8+ (B) T cells. *p < 0.05; **p < 0.01.
FIGURE 1 | Immunophenotypic characterization of dendritic cells generated 
within 3 days based on a TLR7/8 ligand (TLR-3-DCs). TLR-3-DCs were 
generated from peripheral blood of healthy donor (HDs), and surface marker 
expression was measured by flow cytometry. (A) The characteristic 
phenotype of a dendritic cell population (FSChi/SSChi/CD14-/CD83+/
CD80+/CD86+) is shown for one representative donor. (B) Expression of 
various inhibitory checkpoint molecules was analyzed on TLR-3-DCs of 3–10 
donors, and MFI ratio of the expression is presented as box-and-whisker 
plots.
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representing the lower quartile, the median and the upper 
quartile, while the whiskers show the minimal and the maximal 
value. The significance of differences for pairwise comparison 
was determined using the two-tailed Wilcoxon signed rank test. 
p < 0.05 was considered statistically significant (* in all figures), 
while p < 0.01 is termed highly significant (** in all figures).
RESULTS
TLR-3-DCs Expressed PD-L1 and HLA-DR
TLR-3-DCs were generated from PB of HDs. The characteristic 
phenotype of these DCs, with high expression of CD83, CD86, 
and CD80 and downregulation of CD14 is shown in Figure 1A. 
Expression of various inhibitory checkpoint molecules on DCs 
was analyzed by flow cytometry on 3–10 of these samples. 
HLA-DR was added to the panel as ligand for lymphocyte activa-
tion gene 3 (LAG-3) on T cells. MFI ratio of the expression data is 
presented in Figure 1B, statistical significance was tested against 
a theoretical median of 1.5. The expression of PD-L1 (median 6.2; 
n = 7; p = 0.004) and HLA-DR (median 184.5; n = 7; p = 0.016) 
on TLR-3-DCs was found to be (highly) significant. By contrast, 
HVEM (median 2.0; n = 10), CD48 (median 2.5; n = 7), Gal-9 
(median 0.8; n = 7), and PD-L2 (median 0.9; n = 3) were not 
significantly expressed (Figure 1B).
CD244, TIM-3, PD-1, and LAG-3 Were 
Upregulated on T Cells after Stimulation 
with TLR-3-DCs
Expression of the respective co-inhibitory ligands was determined 
on T cells with and without stimulation by DCs. TLR-3-DCs were 
generated from PB of HDs and pulsed with CEFT peptide pool. 
CD3+ T cells were isolated from PB of the same HDs and cocul-
tured with autologous DCs or with CEFT peptide pool alone for 
96 h. Expression of various inhibitory checkpoint molecules was 
analyzed on T cells by flow cytometry for 7–14 HDs. The percent-
age of positive cells is presented for CD4+ (Figure 2A; Figure S1 
in Supplementary Material) and CD8+ (Figure  2B; Figure S1 
in Supplementary Material) T  cells. Statistical significance was 
tested between stimulation with pulsed DCs and CEFT stimula-
tion alone as a control. CD4+ T cells showed a (highly) significant 
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upregulation of CD244 (median of 2.3 vs. 1.5%; n = 7; p = 0.047), 
TIM-3 (median of 24.3 vs. 4.2%; n = 7; p = 0.016) and PD-1 
(median of 16.4 vs. 5.9%; n = 13; p = 0.003) after stimulation 
with TLR-DCs, while expression of CD160 (median of 3.3 vs. 
5.9%; n = 7) and LAG-3 (median of 1.8 vs. 0.7%; n = 9) were not 
changed (Figure 2A). On CD8+ T cells, we found (highly) sig-
nificant upregulation of CD244 (median of 30.2 vs. 13.9%; n = 8; 
p = 0.008), TIM-3 (median of 30.8 vs. 3.9%; n = 8; p = 0.008), 
PD-1 (median of 21.5 vs. 13.4%; n = 14; p < 0.001) and LAG-3 
(median of 5.4 vs. 0.4%; n = 9; p = 0.027), but not of CD160 
(median of 4.5% vs. 5.0%; n = 8) (Figure 2B).
Blockade of PD-1 and LAG-3, but Not 
HVEM, CD244 or TIM-3, Enhanced 
Proliferation of T Cells after Stimulation 
with TLR-3-DCs
In order to determine the functional relevance of co-inhibitory 
molecule interaction between TLR-3-DCs and T  cells, we first 
tested the influence of checkpoint blockade on proliferation of 
T cells after DC stimulation. CD3+ T cells isolated from PB of 
HDs were labeled with CFSE and cocultured with autologous 
CEFT-pulsed TLR-3-DCs for 5 days in the presence or absence 
of respective blocking antibodies. The percentage of divided 
cells was determined by flow cytometry. The ratio between the 
percentages of divided cells with and without blocking antibody 
was calculated. Data for 4–13 samples is presented in Figure 3A 
for CD4+ T  cells and in Figure 3B for CD8+ T  cells, original 
data is shown in Table S1 in Supplementary Material. Statistical 
significance was calculated against a fold change of 1.0, equal to 
no effect of the blocking antibody on proliferation. For CD4+ 
T  cells, no effect of checkpoint blockade on proliferation was 
found for HVEM (fold change 0.91; n = 6), CD244 (fold change 
1.05; n = 4) and TIM-3 (fold change 1.02; n = 4). Blockade of 
PD-1 resulted in slightly enhanced proliferation (fold change 
1.15; n = 13; p = 0.002), and blockade of LAG-3 lead to markedly 
enhanced proliferation (fold change 1.44; n = 9; p = 0.002), both 
statistically highly significant (Figure 3A). Similarly, for CD8+ 
T cells, blockade of PD-1 resulted in slightly enhanced prolifera-
tion (fold change 1.08; n = 13; p = 0.003), and blockade of LAG-3 
lead to markedly enhanced proliferation (fold change 1.24; n = 9; 
p = 0.002), both statistically highly significant, while no effect of 
checkpoint blockade on proliferation was found for HVEM (fold 
change 0.88; n = 6), CD244 (fold change 0.96; n = 4) and TIM-3 
(fold change 0.91; n = 4) (Figure 3B).
Blockade of PD-1 and LAG-3, but Not 
HVEM, CD244 or TIM-3, Enhanced IFN-γ 
and TNF-α Secretion by T Cells after 
Stimulation with TLR-3-DCs
Next, we determined whether checkpoint blockade also influ-
enced IFN-γ and TNF-α secretion by T cells after DC stimula-
tion. CD3+ T cells isolated from PB of HDs were cocultured with 
autologous CEFT-pulsed TLR-3-DCs for 96 h in the presence or 
absence of respective blocking antibodies. The concentration of 
IFN-γ and TNF-α in the culture supernatant was determined by 
CBA. IFN-γ and TNF-α fold change was calculated by dividing 
the concentration of the coculture with blocking antibody by the 
concentration of the control coculture without antibody. Data 
for 5–14 samples is presented for IFN-γ in Figure 3C, statistical 
significance was calculated against a fold change of 1.0, original 
data are shown in Table S1 in Supplementary Material. No effect 
of checkpoint blockade on IFN-γ secretion was found for HVEM 
(fold change 0.63; n = 7), CD244 (fold change 0.86; n = 5), and 
TIM-3 (fold change 1.01; n = 5). Blockade of PD-1 resulted in 
enhanced IFN-γ secretion (fold change 1.50; n = 14; p = 0.002) 
and blockade of LAG-3 lead to markedly enhanced IFN-γ secre-
tion (fold change 5.00; n = 9; p = 0.004), both statistically highly 
significant (Figure 3C). Similarly, no effect of checkpoint block-
ade on TNF-α secretion was found for HVEM (fold change 0.89; 
n = 7), CD244 (fold change 1.01; n = 5) and TIM-3 (fold change 
0.92; n = 5), while blockade of PD-1 (fold change 1.69; n = 14; 
p =  0.002), and blockade of LAG-3 (fold change 5.29; n =  9; 
p = 0.008) resulted in enhanced TNF-α secretion, both statisti-
cally highly significant (Figure S2 in Supplementary Material).
Combination with PD-1 Blockade Resulted 
in an Increase of IFN-γ Secretion, but Not 
in an Enhanced Proliferation of T Cells 
after Stimulation with TLR-3-DCs 
Compared to LAG-3 Blockade Alone
We tested the hypothesis that blockade of PD-1 and LAG-3 has 
additive or synergistic effects on proliferation or IFN-γ secretion 
by T  cells after stimulation with TLR-3-DCs. For proliferation 
assays, CD3+ T cells isolated from PB of 7 HDs were labeled with 
CFSE and cocultured with autologous TLR-3-DCs for 5  days 
in the presence or absence of blocking antibodies for PD-1 and 
LAG-3, both alone and in combination. As above, the percentage 
of divided cells was determined by flow cytometry for the differ-
ent conditions, and the ratio between the percentages of divided 
cells with and without blocking antibody was calculated. Data 
are presented in Figure 3D for CD4+ T cells and in Figure 3E 
for CD8+ T  cells, statistical significance was calculated for the 
combination of blocking antibodies vs. single antibody blockade, 
original data are shown in Table S1 in Supplementary Material. 
For the combination of PD-1 and LAG-3 blockade (median 
fold change of 1.37 for CD4+ and 1.26 for CD8+), we found sig-
nificantly higher T cell proliferation compared to PD-1 blockade 
alone (median fold change of 1.02 for CD4+; p = 0.016; 1.02 for 
CD8+; p = 0.016), but no difference to LAG-3 blockade alone 
(median fold change of 1.31 for CD4+; p = 0.094; 1.20 for CD8+; 
p = 0.250).
Similarly, for IFN-γ secretion assays, CD3+ T  cells isolated 
from PB of 8 HDs were cocultured with autologous CEFT-pulsed 
TLR-3-DCs for 96 h in the presence or absence of blocking anti-
bodies for PD-1 and LAG-3, both alone and in combination. The 
concentration of IFN-γ in the culture supernatant was determined 
by CBA. IFN-γ fold change was calculated as a ratio between the 
IFN-γ concentration of the coculture with and without blocking 
antibody. Statistical significance was calculated for the combina-
tion of blocking antibodies vs. single antibody blockade. For the 
combination of PD-1 and LAG-3 blockade (median fold change 
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FIGURE 3 | Effect of immune checkpoint blockade on proliferation and IFN-γ secretion of T cells after stimulation with TLR-3-DCs. CD3+ T cells of 4–14 healthy donor 
(HDs) were cocultured with autologous CMV, EBV, influenza, tetanus (CEFT)-pulsed TLR-3-DCs in the presence or absence of immune checkpoint blocking antibodies, 
either for individual antibodies (A–C) or in different combinations of α-PD-1 and α-LAG-3 antibodies (D–F). Proliferation of CD4+ (A,D) and CD8+ T cells (B,E) was 
analyzed by carboxyfluorescein N-succinimidyl ester (CFSE) assay, and the ratio between the percentages of divided cells with and without blocking antibody was 
calculated. IFN-γ secretion of CD3+ T cells (C,F) was determined by cytometric bead array (CBA) assay, and the ratio between concentration with and without blocking 
antibody was calculated. All data are presented as box-and-whisker plots, and statistical significance was calculated against a fold change of 1.0. *p < 0.05; **p < 0.01.
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FIGURE 4 | Effect of programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) blockade on IFN-γ secretion of different T cell 
subpopulations after stimulation with TLR-3-DCs. MACS-enriched CD3+ T cells of 8 healthy donor (HDs) were sorted according to CCR7 and CD45 RA expression 
(A). The various T cell subpopulations were cocultured with autologous CMV, EBV, influenza, tetanus (CEFT)-pulsed TLR-3-DCs in the presence or absence of 
α-PD-1 (B) and α-LAG-3 (C) antibody. IFN-γ secretion was determined by cytometric bead array (CBA) assay, and the ratio between concentration with and without 
blocking antibody was calculated. All data are presented as box-and-whisker plots, and statistical significance was calculated against a fold change of 1.0. 
*p < 0.05.
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of 2.80), the increase in IFN-γ secretion compared to PD-1 block-
ade alone was statistically highly significant (median fold change 
of 1.41; p = 0.008). In comparison to LAG-3 blockade alone, we 
found a slight, but statistically significant enhancement (median 
fold change of 2.70; p  =  0.016) (Figure  3F). Taken together, 
LAG-3 blockade alone resulted in strong enhancement of T cell 
proliferation and IFN-γ secretion. The effect on IFN-γ secretion 
was slightly increased by the combination with PD-1 blockade, 
while no additional effect was seen for T cell proliferation.
LAG-3 Blockade Mainly Enhanced IFN-γ 
Secretion by Naive and TCM, While PD-1 
Blockade Also Resulted in an Increase of 
IFN-γ Secretion by Effector Memory Cells
Next, we analyzed the differential effect of PD-1 and LAG-3 
blockade on T  cell subpopulations. MACS-enriched CD3+ 
T  cells were sorted according to CCR7 and CD45RA expres-
sion levels into Tnaive, TCM, TEM, and TEMRA T cells (Figure 4A). 
The various T cell populations were cocultured with autologous 
CEFT-pulsed TLR-3-DCs for 96 h in the absence of presence 
of blocking antibodies for PD-1 and LAG-3. Again, the con-
centration of IFN-γ in the culture supernatant was determined 
by CBA. IFN-γ fold change was calculated by dividing the 
concentration of the coculture with blocking antibody by the 
concentration of the control coculture without antibody. Data 
for six samples is presented for PD-1 (Figure 4B) and for LAG-3 
(Figure  4C) blockade. Statistical significance was calculated 
against a fold change of 1.0. We found that PD-1 blockade lead 
to significantly increased IFN-γ secretion of Tnaive (median fold 
change of 1.41; p = 0.031), TCM (median fold change of 1.43; 
p = 0.031), and TEM (median fold change of 1.47; p = 0.031), 
while the increased secretion of TEMRA was not statistically 
significant (median fold change of 1.96; p = 0.156) (Figure 4B). 
By contrast, LAG-3 blockade had significant effects on IFN-γ 
secretion of Tnaive (median fold change of 2.04; p = 0.031) and TCM 
(median fold change of 1.71; p = 0.031), but not on TEM (median 
fold change of 1.34; p = 0.094) and TEMRA (median fold change 
of 1.33; p =  0.094) (Figure 4C). With respect to the CD25+/
FoxP3+ regulatory T cell subpopulation of CD4+ T cells, we saw 
a tendency toward a higher percentage after LAG-3 blockade 
(Figure S3 in Supplementary Material).
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FIGURE 5 | Effect of programmed cell death protein 1 (PD-1) and 
lymphocyte activation gene 3 (LAG-3) blockade on proliferation of EBV 
antigen-specific T cells after stimulation with TLR-3-DCs. non-adherent cell 
(NACs) of 9 healthy donor (HDs) were cocultured with autologous 
Epstein–Barr nuclear Ag 3 A peptide FLRGRAYGL (FLR)-pulsed TLR-3-DCs 
in the presence or absence of α-PD-1 and α-LAG-3 antibody. (A) The 
percentage of FLR tetramer positive cells within the CD8+ T cell population 
was determined by flow cytometry. Data for fold change to the condition 
without blocking antibody are presented as box-and-whisker plots, and 
statistical significance was calculated against a fold change of 1.0. 
*p < 0.05. (B) PD-1 and LAG-3 expression was determined for FLR 
tetramer positive CD8+ T cells after stimulation with non-pulsed or 
FLR-pulsed TLR-3-DCs.
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Blockade of LAG-3, but Not PD-1, 
Enhanced Proliferation of EBV Antigen-
Specific T Cells after Stimulation with 
TLR-3-DCs
Next, we tested whether blockade of PD-1 and LAG-3 also 
enhances the proliferation of antigen-specific T cells after stimu-
lation with TLR-3-DCs. NACs (mainly consisting of T cells) of 9 
HDs were cocultured with autologous FLR-pulsed TLR-3-DCs 
for 144 h in the presence or absence of blocking antibodies for 
PD-1 and LAG-3, both alone and in combination. The percent-
age of FLR tetramer positive (Tet+) cells within the CD8+ T cell 
population was determined by flow cytometry. Tet+ fold change 
was calculated by dividing the percentage in the condition with 
blocking antibody by the percentage in the condition without 
any antibody. Statistical significance was calculated against a 
fold change of 1.0. Blockade of LAG-3 resulted in a significantly 
increased percentage of Tet+ CD8+ T cells (median fold change 
1.69; p = 0.039), while blockade of PD-1 (median fold change 
0.79) and the combination of LAG-3 and PD-1 blockade (median 
fold change 0.61) did not enhance the percentage of antigen-
specific T cells (Figure 5A). This was not due to a lack of PD-1 
expression on T cells, as further analysis of the Tet+ CD8+ T cells 
after stimulation with FLR-pulsed DCs revealed that PD-1 was 
expressed on 92.6% of the T cells, while LAG-3 was found on only 
49.1% of T cells (Figure 5B).
Blockade of LAG-3, but Not PD-1, 
Enhanced Proliferation and IFN-γ 
Secretion of T Cells after Stimulation with 
FLR-Pulsed APCs within PBMCs
We then asked if the effect of LAG-3 blockade on proliferation 
and IFN-γ secretion also holds true, if T cells are not stimulated 
by TLR-3-DCs, but by the various APCs naturally occurring 
within PBMCs. PBMCs of 8 HDs were pulsed with FLR peptide 
and cultured for 6 days in the presence or absence of blocking 
antibodies for PD-1 and LAG-3, both alone and in combina-
tion. Thereafter, the percentage of FLR tetramer positive cells 
(Tet+) within the CD8+ T  cell population was determined 
by flow cytometry. Tet+ fold change was calculated by divid-
ing the percentage in the condition with blocking antibody 
by the percentage in the condition without any antibody. 
Statistical significance was calculated against a fold change of 
1.0. Blockade of LAG-3 resulted in a significantly increased 
percentage of Tet+ CD8+ T  cells (median fold change 1.80; 
p = 0.023), while blockade of PD-1 (median fold change 1.05) 
did not enhance the percentage of antigen-specific T cells. The 
combination of LAG-3 and PD-1 blockade also significantly 
enhanced the percentage of Tet+ CD8+ T  cells (median fold 
change 1.74; p = 0.016), but this was not different from LAG-3 
alone (p = 0.461) (Figure 6A).
The concentration of IFN-γ was determined in the culture 
supernatant after 6–8  days of coculture by CBA. IFN-γ fold 
change was calculated by dividing the concentration of the cocul-
ture with blocking antibody by the concentration of the control 
coculture without antibody. Data for the same eight samples is 
presented in Figure  6B, statistical significance was calculated 
against a fold change of 1.0. Blockade of PD-1 (median fold 
change 0.96) did not enhance IFN-γ secretion, while increase 
of IFN-γ secretion after blockade of LAG-3 was highly signifi-
cant (median fold change 4.07; p = 0.008). The combination of 
LAG-3 and PD-1 blockade also enhanced IFN-γ secretion highly 
significantly (median fold change 6.88; p = 0.008), but the dif-
ference to LAG-3 blockade alone was not significant (p = 0.188) 
(Figure 6B).
Further analysis of the Tet+ CD8+ T cells after stimulation with 
FLR-pulsed PBMCs revealed that PD-1 was expressed on almost 
all of the T cells (93.3%), while LAG-3 was found on only 10.5% 
of T cells (Figure 6C). Therefore, the non-existent effect of PD-1 
blockade in this setting was not due to an absence of PD-1 on the 
T cell surface.
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FIGURE 6 | Effect of programmed cell death protein 1 (PD-1) and 
lymphocyte activation gene 3 (LAG-3) blockade on proliferation and IFN-γ 
secretion of EBV antigen-specific T cells after stimulation with antigen-
presenting cells (APC) within peripheral blood mononuclear cells (PBMCs). 
Epstein–Barr nuclear Ag 3 A peptide FLRGRAYGL (FLR) peptide-pulsed 
PBMCs of 8 healthy donor (HDs) were cultered in the presence or absence of 
α-PD-1 and α-LAG-3 antibody. The percentage of FLR tetramer positive cells 
within the CD8+ T cell population was determined by flow cytometry (A), and 
IFN-γ secretion was determined by cytometric bead array (CBA) assay (B). 
Data for fold change to the condition without blocking antibody are 
presented as box-and-whisker plots, and statistical significance was 
calculated against a fold change of 1.0. * p < 0.05; **p < 0.01. (C) PD-1 and 
LAG-3 expression was determined for FLR tetramer positive CD8+ T cells 
after stimulation with non-pulsed or FLR-pulsed PBMCs.
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Blockade of LAG-3, More than PD-1, 
Enhanced Expansion of WT1 Tumor 
Antigen-Specific T Cells after Stimulation 
with TLR-3-DCs
Finally, we tested the hypothesis that the effect of LAG-3 
blockade on proliferation of antigen-specific T cells can also be 
transferred to tumor antigen specificity. CD8+ T cells of 3 HDs 
were cocultured with autologous TLR-3-DCs pulsed with a WT1 
antigen (VLD peptide) for 6–7 days in the presence or absence of 
blocking antibodies for PD-1 and LAG-3. The percentage of VLD 
tetramer positive (Tet+) cells within the CD8+ T cell population 
was determined by flow cytometry. Results for all three donors 
are presented in Figure  7. Blockade of LAG-3 resulted in an 
increased percentage of Tet+ CD8+ T cells in two of three cases, 
while blockade of PD-1 resulted in an increase in Tet+ CD8+ 
T cells in only one case, and to a lesser extent.
DISCUSSION
Over the last decades, DCs generated in vitro for the vaccination 
of tumor patients have been optimized with respect to cytokine 
production as well as co-stimulatory molecule expression. 
However, even TLR-3-DCs, which demonstrate an improved 
phenotype and functional profile, express co-inhibitory molecules 
(9). Combining DC vaccination with checkpoint inhibition is, 
therefore, conceivable and might enhance T cell responses.
In this study, we systematically analyzed the effect of different 
checkpoint inhibitors on T cell stimulation by TLR-3-DCs. We 
found that within our experimental settings, blockade of LAG-3 
was consistently superior to PD-1 blockade, independently of 
the method to measure T cell stimulation (proliferation, IFN-γ 
secretion), the stimulating antigen (viral and bacterial peptide 
pool, specific viral antigen, specific tumor antigen), and the type 
of T cell (CD4+ and CD8+ T cells) used. This was not expected, 
as LAG-3 expression on T  cells is relatively low compared to 
PD-1 expression and only slightly upregulated after stimulation. 
However, it has to be considered that checkpoint molecules are 
often upregulated on antigen-specific T  cells only (Figure S4A 
in Supplementary Material) and, thus, the assessment of bulk 
T  cell populations might only insufficiently reflect checkpoint 
molecule expression. Besides, HLA-DR as the main ligand for 
LAG-3 is much higher expressed on APCs including TLR-3-DCs 
than any co-inhibitory molecules (Figure 1), conceivably result-
ing in numerous receptor–ligand interactions with T cells that 
help to explain the strong effects seen in our blocking experi-
ments. LSECtin, a cell surface lectin of the DC-SIGN family, has 
been identified as an alternative ligand for LAG-3, and LAG-3 
blockade has been shown to result in abrogation of immunoin-
hibitory effects of LSECtin in a melanoma mouse model (34). As 
LSECtin is only marginally expressed on TLR-3-DCs (Figure S5 
in Supplementary Material), the effects of LAG-3 blockade dem-
onstrated here are more likely due to interaction with HLA-DR. 
Similarly, the low PD-L2 expression on DCs suggests that PD-L1 
is more relevant for the interaction with PD-1 in our setting. 
However, we cannot rule out that other receptor–ligand interac-
tions between DCs and T cells that have not yet been explored are 
responsible for the effects on T cell responses that we describe. In 
order to further elucidate the mechanism of action, a potential 
approach could be the application of MHC class II blocking 
antibodies. In a model using COS-7 cells transfected with human 
LAG-3 and MHC class II-expressing human B lymphoblastic cell 
lines, it could be shown that both blocking antibodies against 
LAG-3 and HLA-DR were able to disrupt the rosettes formed by 
these cells (23). However, the exact binding site on MHC class 
II for LAG-3 is still unknown making the choice of an antibody 
that specifically blocks the interaction of MHC II with LAG-3 
technically challenging.
In a recently published study that analyzed the effects of 
checkpoint blockade on T cell stimulation by allogeneic DCs, the 
addition of an antibody directed against LAG-3 to the coculture 
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FIGURE 7 | Effect of programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) blockade on proliferation of Wilms Tumor 1 tumor-antigen-
specific T cells after stimulation with TLR-3-DCs. CD8+ T cells of three healthy donor (HDs) were cocultured with autologous VLD-pulsed. TLR-3-DCs in the 
presence or absence of α-PD-1 and α-LAG-3 antibody. The percentage of VLD tetramer positive cells within the CD8+ T cell population was determined by flow 
cytometry. Data for all three donors are shown.
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did not result in significant changes in T  cell proliferation or 
cytokine secretion (21). As the setting of these experiments dif-
fered from ours in the origin of the blood donors (allogeneic vs. 
autologous), maturation protocol of the DCs and target antigens, 
there are multiple reasons for the diverging results. However, it 
is also important to notice that the LAG-3 antibody used is of a 
different clone and its blockade of the ligand–receptor interac-
tions might be less effective than in our experiments. While we 
did not directly proof that the antibodies we used were blocking 
the interaction with their ligands, we only chose antibodies that 
had been described in the literature to have this capacity. Besides, 
we showed that addition of the blocking antibodies reduced the 
capacity of the respective staining antibody to bind to the recep-
tor (Figure S4B in Supplementary Material).
While the effects of PD-1 blockade on T cell stimulation by 
TLR-3-DCs were less pronounced than those of LAG-3 blockade 
in our experiments, they were still significant. Surprisingly, how-
ever, the combination of both blocking antibodies did not result 
in a relevant increase in T cell stimulation compared to the LAG-3 
antibody alone. In the analysis of viral antigen-specific T  cell 
stimulation, it was even deleterious (Figure 5). Several murine 
tumor models, including a B16 melanoma and an MC38 colon 
adenocarcinoma model (31) demonstrated synergistic anti-tumor 
immunity by dual blockade of PD-1 and LAG-3. One possible 
explanation for our observation is an overstimulation of T cells 
by the combination of the immunostimulatory TLR-3-DCs with 
two effective checkpoint inhibitors. This is in line with data pub-
lished for chronic lymphocytic leukemia, where PD-1 blockade 
abolished the positive effect induced by anti-LAG-3 antibodies in 
combination with CD3/CD28 beads as a very strong stimulus (35).
This hypothesis was substantiated in our experiments 
using PBMCs, comprising APCs that are relatively less 
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immunostimulatory compared to TLR-3-DCs. Here, the combi-
nation of both blocking antibodies resulted in T cell stimulation 
that was at least similar to the LAG-3 antibody alone (Figure 6). 
As the strength of the antigen stimulus is also dependent on pep-
tide concentration, we conducted peptide titration assays in the 
setting of viral antigen-specific T cell stimulation both by TLR-
3-DCs and by PBMCs (Figure S6 in Supplementary Material). 
At the lowest peptide concentration, the combinatorial blockade 
was equally effective to LAG-3 blockade alone for DCs, while the 
effect of LAG-3 blockade on PBMCs was strongly increased by 
the addition of PD-1 blockade. Thus, we provide evidence that 
LAG-3 blockade alone is effective in boosting of T cell stimula-
tion by a strong antigenic stimulus, while the combination of 
LAG-3 and PD-1 blockade is more effective in the setting of weak 
T cell stimulation. This observation is in line with ex vivo T cell 
stimulation experiments with tumor-infiltrating lymphocytes of 
epithelial ovarian cancer patients, where dual blockade of LAG-3 
and PD-1 during priming of tumor antigen-specific T cells with 
tumor-derived APCs as weak stimulators increased T cell effector 
function to the levels observed with PB-derived APCs as stronger 
stimulators (32).
Our data set is focused on the priming phase of the immune 
response rather than the effector phase. The expression levels 
of checkpoint molecules on APCs clearly differ from those on 
tumor cells. Therefore, it is not surprising that the dominant 
effect of LAG-3 blockade and the relatively low effect of PD-1 
blockade that we see deviates from the results in animal studies 
(36) and the outstanding clinical effects observed with PD-1 
blockade as monotherapy or in combination with antineoplastic 
agents in clinical trials for various tumor entities. The effects 
observed in those studies rely on the effector phase of the 
immune response and are dependent on pre-existing effector 
T cells. Different immune checkpoints seem to be of importance 
in priming and effector phase, as directly shown for the epithelial 
ovarian cancer model, where LAG-3 blockade did not influ-
ence the effector function of already primed tumor-infiltrating 
T cells (32). Similarly, a 4-1BB agonist was more effective than 
an anti-LAG-3 blocking antibody as a combination partner for 
PD-1 blockade in a melanoma mouse model in the absence of 
any cancer vaccine (37). Recently, first data was published from 
an ongoing clinical trial (NCT01968109), in which anti-LAG-3 
in combination with anti-PD-1 showed activity in melanoma 
patients who were relapsed or refractory to anti-PD-1/-PD-L1 
therapy. The objective response rate (ORR) was 11.5% in 61 
efficacy-evaluable patients, and a correlation of higher ORR with 
a LAG-3 expression above 1% on tumor-associated immune cells 
was shown (38).
Checkpoint blockade has revolutionized cancer therapy in 
several entities, including melanoma, lung cancer, and urothelial 
carcinoma. To our current understanding, these results primarily 
rely on reversing adaptive immune escape mechanisms of the 
tumor cells in the context of an immune response. Our data, 
however, support the relevance of checkpoint inhibition within 
the induction of primary or secondary anti-tumor immune 
responses. Thus, checkpoint inhibitors might also be therapeu-
tically beneficial in tumor entities with a non-immunogenic 
microenvironment. Further studies will be needed to address 
the question of checkpoint inhibition within the priming versus 
effector phase of T cell responses. The sequencing and exact tim-
ing of LAG-3 and PD-1 blockade might be of particular relevance 
for the induction for optimal anti-tumor T cell responses.
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Figure S1. Upregulation of immune checkpoint ligands on T cells after DC stimulation. 
T cells were cocultured with autologous TLR-3-DCs pulsed with CEFT peptide pool. 
Expression of various inhibitory checkpoint molecules after 4 days of coculture was analyzed 
by flow cytometry. Original histogram data are shown for one representative donor.   
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Figure S2. Effect of immune checkpoint blockade on TNF-a secretion of T cells after 
stimulation with TLR-3-DCs. CD3+ T cells of 4–14 HDs were cocultured with autologous 
CEFT-pulsed TLR-3-DCs in the presence or absence of immune checkpoint blocking 
antibodies, either for individual antibodies (A) or in different combinations of α-PD-1 and α-
LAG-3 antibodies (B). TNF-a secretion of CD3+ T cells was determined by CBA assay, and 
the ratio between concentration with and without blocking antibody was calculated. All data 
are presented as box-and-whisker plots, and statistical significance was calculated against a 
fold change of 1.0. *, p<0.05; **, p<0.01.   
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Figure S3. Effect of LAG-3 blockade on percentage of regulatory T cells after 
stimulation with TLR-3-DCs. CD3+ T cells were cocultured with autologous CEFT-pulsed 
TLR-3-DCs in the presence or absence of α-LAG-3 antibody. Within the CD4+ T cell 
population, co-expression of CD25 and FoxP3 was determined by flow cytometry. Data are 
shown for one representative donor, demonstrating a relative increase in percentage of 
regulatory T cells after LAG-3 blockade.  
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Figure S4. Competition between blocking antibodies and staining antibodies for LAG-3 
and PD-1 on EBV antigen-specific T cells after stimulation with TLR-3-DCs. DCs were 
pulsed with FLR peptide and cocultured with autologous NAC in the presence or absence of 
α-PD-1 and α-LAG-3 blocking antibodies. Expression of PD-1 and LAG-3 positive cells 
within the FLR tetramer-positive cells of the CD8+ T cell population was determined by flow 
cytometric measurements with respective staining antibodies. Data are shown for one 
representative donor.   
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Figure S5. LSECtin expression of immature DCs and TLR-3-DCs. DCs were generated 
from PB of HDs, and surface marker expression was measured by flow cytometry. LSECtin 
expression of immature DCs (A), harvested on d2 of DC generation, before addition of 
maturation cocktail, and LSECtin expression of mature TLR-3-DCs (B), harvested on d3, 
after 24 hours with maturation cocktail, is shown for one representative donor.  
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Figure S6. Effect of PD-1 and LAG-3 blockade on proliferation of EBV antigen-specific 
T cells after stimulation with PBMCs or TLR-3-DCs using different peptide 
concentrations. PBMCs (A) and TLR-3-DCs (B) were pulsed with FLR peptide in different 
dilutions and cocultured with NACs in the presence or absence of α-PD-1 and α-LAG-3 
antibodies. The percentage of FLR tetramer-positive cells within the CD8+ T cell population 
was determined by flow cytometry. Data for fold change to the condition without blocking 
antibody are shown for one representative donor.   
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Table S1. Effect of immune checkpoint blockade on proliferation and IFN-γ secretion of 
T cells after stimulation with TLR-3-DCs. Original data on which Figure 3 is based.   
A+D CD4++DC+CEFT Ctrl  
aHVEM 
 
aCD244 
 
aTIM3 
 
aPD-1 
 
aLAG-3 
 
aPD-1+ 
aLAG-3 
 
HD1 % divided 32.20 32.10 32.40 23.30 35.10     
HD2 % divided 10.80 10.60 10.40 11.00 13.30     
HD3 % divided 11.40 8.94 9.85 10.50 12.30     
HD4 % divided 13.60 15.10 13.90 12.10 15.30     
HD5 % divided 33.10         38.90   
HD6 % divided 16.90       17.20 37.20   
HD7 % divided 10.00       12.40 21.80   
HD8 % divided 21.70 3.30     21.40 50.10 49.80 
HD9 % divided 42.70 13.50     44.70 54.20 51.60 
HD10 % divided 15.70       39.00 37.50 47.10 
HD11 % divided 30.10       34.10 35.70 38.00 
HD12 % divided 50.00       51.00 59.80 70.80 
HD13 % divided 37.00       36.50 42.80 43.10 
B+E CD8
++DC+CEFT 
 
Ctrl 
 
aHVEM 
 
aCD244 
 
aTIM3 
 
aPD-1 
 
aLAG-3 
 
aPD-1+ 
aLAG-3 
HD15 % divided 29.60 29.50 31.10 19.60 32.10     
HD16 % divided 11.50 10.90 11.80 12.00 14.10     
HD17 % divided 9.33 8.26 9.81 9.30 11.80     
HD18 % divided 12.70 11.80 13.40 13.20 15.10     
HD19 % divided 35.10         43.70   
HD20 % divided 10.30       12.00 22.80   
HD21 % divided 10.90       13.80 24.20   
HD22 % divided 14.60 2.99     16.30 36.10 53.30 
HD23 % divided 39.00 31.60     39.40 61.00 60.90 
HD24 % divided 8.82       11.60 22.80 24.90 
HD25 % divided 19.50       19.80 24.60 25.10 
HD26 % divided 41.60       39.00 44.10 46.70 
HD27 % divided 37.90       38.50 43.60 41.90 
C+F 
CD3+ 
+DC+CEFT  
IFNg 
Ctrl 
 
aHVEM 
 
aCD244 
 
aTIM3 
 
aPD-1 
 
aLAG-3 
 
aPD-1+ 
aLAG-3 
HD29 pg/mL 398.63 387.30 715.76 402.48 964.74    
HD30 pg/mL 1381.55 541.91 1229.15 1523.45 9228.35    
HD31 pg/mL 194.64 123.56 142.63 138.33 256.26    
HD32 pg/mL 313.29 172.33 268.29 177.56 483.00    
HD33 pg/mL 851.05 304.34 516.54 946.29 787.98    
HD34 pg/mL 3485.22       4411.02    
HD35 pg/mL 594.75         2846.31  
HD36 pg/mL 378.06       620.73 3666.30  
HD37 pg/mL 8291.48       28491.01 271494.80  
HD38 pg/mL 2009.66       2733.42 5047.71 5513.86 
HD39 pg/mL 15948.00       10193.00 27906.00 39155.00 
HD40 pg/mL 937.11       1370.81 9714.00 12249.00 
HD41 pg/mL 62772.98       69980.57 793222.10 940013.10 
HD42 pg/mL 704.90 777.35     1340.94 3522.41 3609.71 
HD43 pg/mL 1922.88 2321.78     3813.53 5553.99 5483.80 
HD44 pg/mL 989.40       958.00 1593.60 2145.30 
HD45 pg/mL 1121.40       2089.00 1837.00 2488.20 
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